Lighting Science (LSCG) 10-K 14 Apr 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 29, 2016	Jun. 30, 2015
Entity Registrant Name	LIGHTING SCIENCE GROUP CORP
Entity Central Index Key	866,970
Trading Symbol	lscg
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		210,302,131
Entity Public Float			$ 8.2
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Series H Preferred Stock [Member]
Current liabilities:
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 227,220,149	$ 227,220,149
Stockholders' deficit:
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	135,000	135,000
Series I Preferred Stock [Member]
Current liabilities:
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 124,736,627	$ 124,736,627
Stockholders' deficit:
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	90,000	90,000
Series J Preferred Stock [Member]
Current liabilities:
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 160,124,000	$ 116,950,000
Stockholders' deficit:
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	85,100	85,100
Series K Preferred Stock [Member]
Current liabilities:
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 20,106,030	$ 0
Stockholders' deficit:
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	40,000	40,000
Cash and cash equivalents	$ 647,526	$ 1,609,297
Restricted cash	3,000,000	3,000,000
Accounts receivable, net	7,673,352	10,417,985
Inventories, net	21,449,721	22,726,162
Prepaid expenses	1,158,818	2,936,837
Other current assets	1,680,331	1,610,544
Total current assets	35,609,748	42,300,825
Property and equipment, net (includes accumulated depreciation of $11.7 million and $10.3 million as of December 31, 2015 and December 31, 2014, respectively)	856,690	2,650,115
Intangible assets, net	3,024,894	2,572,479
Pegasus Commitment	214,400	720,000
Debt issuance costs, less current portion	1,751,171	3,230,446
Other long-term assets	118,448	118,467
Total assets	41,575,351	51,592,332
Lines of credit	6,862,629	6,368,793
Current portion of long-term debt	28,877	58,574
Accounts payable	13,192,756	19,364,552
Provision for losses on non-cancelable purchase commitments	0	540,227
Accrued expenses	7,276,037	9,924,316
Total current liabilities	27,360,299	36,256,462
Note payable	29,232,702	27,813,061
Long-term debt, less current portion	0	35,272
Liabilities under derivative contracts	4,172,809	5,636,944
Total other liabilities	33,405,511	33,485,277
Total liabilities	60,765,810	69,741,739
Series H Redeemable Convertible Preferred Stock, $.001 par value, authorized 135,000 shares, 113,609 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	532,186,806	468,906,776
Commitments and contingencies	$ 0	$ 0
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	0
Common stock, $.001 par value, authorized 975,000,000 shares, 212,803,446 and 212,452,636 shares issued as of December 31, 2015 and December 31, 2014, respectively	$ 212,804	$ 212,453
Additional paid-in capital	281,485,826	320,175,440
Accumulated deficit	(827,416,083)	(800,328,573)
Accumulated other comprehensive loss	(1,902,312)	(3,358,003)
Treasury stock, 2,505,000 shares as of December 31, 2015 and December 31, 2014 , at cost	(3,757,500)	(3,757,500)
Total stockholders’ deficit	(551,377,265)	(487,056,183)
Total liabilities and stockholders’ deficit	$ 41,575,351	$ 51,592,332

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Series H Preferred Stock [Member]
Redeemable Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	135,000	135,000
Redeemable Convertible Preferred Stock, Shares Issued (in shares)	113,609	113,609
Redeemable Convertible Preferred Stock, Shares Outstanding (in shares)	113,609	113,609
Series I Preferred Stock [Member]
Redeemable Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	90,000	90,000
Redeemable Convertible Preferred Stock, Shares Issued (in shares)	62,365	62,365
Redeemable Convertible Preferred Stock, Shares Outstanding (in shares)	62,365	62,365
Series J Preferred Stock [Member]
Redeemable Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	85,100	85,100
Redeemable Convertible Preferred Stock, Shares Issued (in shares)	80,062	58,475
Redeemable Convertible Preferred Stock, Shares Outstanding (in shares)	80,062	58,475
Series K Preferred Stock [Member]
Redeemable Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	40,000	40,000
Redeemable Convertible Preferred Stock, Shares Issued (in shares)	20,106	0
Redeemable Convertible Preferred Stock, Shares Outstanding (in shares)	20,106	0
Accumulated depreciation	$ 11,749,857	$ 10,329,506
Redeemable Convertible Preferred Stock, Authorized Shares (in shares)	0
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	975,000,000	975,000,000
Common stock, Shares Issued (in shares)	212,803,446	212,452,636
Treasury Stock, Shares (in shares)	2,505,000	2,505,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Parent [Member]
Basic and diluted net loss per weighted average common share attributable to controlling stockholders (in dollars per share)	$ (0.19)	$ (0.44)	$ (0.55)
Basic and diluted weighted average number of common shares outstanding attributable to controlling stockholders (in shares)	303,742,731	232,409,186	170,662,220
Noncontrolling Interest [Member]
Basic and diluted net loss per weighted average common share attributable to controlling stockholders (in dollars per share)	$ (0.20)	$ (0.45)	$ (0.55)
Basic and diluted weighted average number of common shares outstanding attributable to controlling stockholders (in shares)	98,598,998	60,001,396	35,070,340
Revenue	$ 79,749,772	$ 91,284,860	$ 83,221,557
Cost of goods sold (exclusive of depreciation shown below)	68,548,508	87,702,728	98,043,280
Gross profit (deficit)	11,201,264	3,582,132	(14,821,723)
Selling, distribution and administrative (includes related party expenses of $0, $919,000 and $2.2 million for 2015, 2014 and 2013, respectively)	22,652,775	34,024,300	51,395,936
Research and development	3,999,727	5,647,568	10,338,799
Restructuring expenses	1,883,326	3,467,835	4,657,497
Depreciation and amortization	1,973,959	3,355,865	8,722,030
Total operating expenses	30,509,787	46,495,568	75,114,262
Loss from operations	(19,308,523)	(42,913,436)	(89,935,985)
Interest income	1,173	8,173	4,749
Interest expense	(6,283,175)	(6,278,878)	(4,026,560)
Related party interest expense	(533,200)	(476,367)
(Increase) decrease in fair value of liabilities under derivative contracts	(598,524)	(15,667,304)	3,892,994
Other (expense) income, net	(348,759)	(266,861)	247,470
Total other (expense) income	(7,762,485)	(22,681,237)	118,653
Loss before income tax expense	(27,071,008)	(65,594,673)	(89,817,332)
Income tax expense	16,502
Net loss	(27,087,510)	(65,594,673)	(89,817,332)
Foreign currency translation adjustment	1,455,691	410,800	(51,172)
Comprehensive loss	$ (25,631,819)	$ (65,183,873)	$ (89,868,504)

Consolidated Statements of Ope5

Consolidated Statements of Operations and Comprehensive (Loss) (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related party expenses	$ 0	$ 919,000	$ 2,200,000

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficit - USD ($)	Series J Preferred Stock [Member]Additional Paid-in Capital [Member]	Series J Preferred Stock [Member]Retained Earnings [Member]	Series J Preferred Stock [Member]AOCI Attributable to Parent [Member]	Series J Preferred Stock [Member]Treasury Stock [Member]	Series J Preferred Stock [Member]	Pegasus Guaranty Warrants [Member]Common Stock [Member]	Pegasus Guaranty Warrants [Member]Additional Paid-in Capital [Member]	Pegasus Guaranty Warrants [Member]Retained Earnings [Member]	Pegasus Guaranty Warrants [Member]AOCI Attributable to Parent [Member]	Pegasus Guaranty Warrants [Member]Treasury Stock [Member]	Pegasus Guaranty Warrants [Member]	Series J Warrants [Member]Additional Paid-in Capital [Member]	Series J Warrants [Member]	Series K Preferred Stock [Member]Additional Paid-in Capital [Member]	Series K Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2012																208,063,486
Balance at Dec. 31, 2012																$ 208,063	$ 347,686,258	$ (644,916,568)	$ (3,717,631)	$ (3,757,500)	$ (304,497,378)
Issuance of restricted stock and options for directors' compensation (in shares)																1,854,507
Issuance of restricted stock and options for directors' compensation																$ 1,854	743,756				745,610
Stock based compensation expense																	7,021,503				7,021,503
Stock issued under equity compensation plans (in shares)																395,175
Stock issued under equity compensation plans																$ 396	38,602				38,998
Deemed dividends on Series H and J Redeemable Convertible Preferred Stock	$ (24,358,592)				$ (24,358,592)
Issuance of common stock in exchange for outstanding Series H Preferred (in shares)																36,000
Issuance of common stock in exchange for outstanding Series H Preferred																$ 36	68,364				68,400
Net loss																		(89,817,332)			(89,817,332)
Foreign currency translation adjustment																			(51,172)		(51,172)
Balance (in shares) at Dec. 31, 2013																210,349,168
Balance at Dec. 31, 2013																$ 210,349	331,199,891	(734,733,900)	(3,768,803)	(3,757,500)	(410,849,963)
Issuance of restricted stock and options for directors' compensation																1,854	743,756				745,610
Series J Warrants reclassified from liability to equity													$ 0
Issuance of restricted stock and options for directors' compensation																1,751	667,888				669,639
Stock based compensation expense																$ 330	3,389,675				3,390,005
Stock issued under equity compensation plans (in shares)																23,126
Stock issued under equity compensation plans																$ 23	6,034				6,057
Deemed dividends on Series H and J Redeemable Convertible Preferred Stock	(62,515,733)	$ 0	$ 0	$ 0	(62,515,733)	$ 0	$ (570,574)	$ 0	$ 0	$ 0	$ (570,574)
Net loss																		(65,594,673)			(65,594,673)
Foreign currency translation adjustment																			410,800		410,800
Balance (in shares) at Dec. 31, 2014																212,452,636
Balance at Dec. 31, 2014																$ 212,453	320,175,440	(800,328,573)	(3,358,003)	(3,757,500)	(487,056,183)
Issuance of restricted stock and options for directors' compensation (in shares)																1,750,342
Issuance of restricted stock and options for directors' compensation																$ 1,751	667,888				669,639
Stock based compensation expense (in shares)																330,000
Warrant issued to a customer																	(13,055)				(13,055)
Warrants issued												$ 10,365,014	10,365,014
Series J Warrants reclassified from liability to equity	37,646,300				37,646,300								37,646,300
Issuance of restricted stock for directors' compensation (in shares)																1,750,342
Stock issued under equity compensation plans (in shares)																9,975
Stock issued under equity compensation plans																$ 10	1,297				1,307
Deemed dividends on Series H and J Redeemable Convertible Preferred Stock	(30,815,616)				(30,815,616)									$ (1,147,766)	$ (1,147,766)
Net loss																		(27,087,510)			(27,087,510)
Foreign currency translation adjustment																			1,455,691		1,455,691
Balance (in shares) at Dec. 31, 2015																212,803,446
Balance at Dec. 31, 2015																$ 212,804	281,485,826	$ (827,416,083)	$ (1,902,312)	$ (3,757,500)	(551,377,265)
Issuance of restricted stock and options for directors' compensation (in shares)																406,835
Stock based compensation expense (in shares)																(66,000)
Warrants issued	$ 8,144,213				$ 8,144,213
Series J Warrants reclassified from liability to equity													$ 0
Issuance of restricted stock for directors' compensation (in shares)																406,835
Issuance of restricted stock for directors' compensation																$ 407	358,264				358,671
Stock based compensation expense																$ (66)	$ 2,171,199				$ 2,171,133
Warrants issued														$ (17,401,205)	$ (17,401,205)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Series J Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series J Redeemable Convertible Preferred Securities	$ 21,538,000	$ 38,475,000	$ 20,000,000
Non-cash investing and financing activities:
Deemed dividends	(30,815,616)	(62,515,733)	(24,358,592)
Series J Warrants reclassified from liability to equity		37,646,300
Series J Warrants [Member]
Non-cash investing and financing activities:
Issuance of Series J Warrants	8,144,213	3,849,742	0
Series J Warrants reclassified from liability to equity	0	37,646,300	0
THD Warrant [Member]
Non-cash investing and financing activities:
Reclass of THD Warrant from equity to liabilities	0	(74,576)	0
Pegasus Guaranty Warrants [Member]
Non-cash investing and financing activities:
Deemed dividends	0	(570,574)	0
Fair value of Pegasus Guaranty included in debt issuance costs	0	(2,766,000)	0
Net loss	(27,087,510)	(65,594,673)	(89,817,332)
Depreciation and amortization	1,973,959	3,355,865	8,722,030
Loss on disposal of subsidiary	1,586,000	0	0
Impairment of plant and equipment	0	636,636	2,420,132
Allocated Share-based Compensation Expense	358,671	669,639	745,610
Stock based compensation expense	2,171,133	3,390,005	7,021,503
Non-cash sales incentive	0	102,500	0
Allowance for doubtful accounts receivable	83,105	103,792	245,151
Write-down of inventory	3,786,113	4,722,436	11,350,469
Provision for Other Losses	115,926	507,257	2,347,905
Increase in fair value of derivative contracts	598,524	15,667,304	(3,892,994)
Amortization of debt issuance costs	1,528,761	1,586,204	506,745
Medley discount accretion	779,072	668,703	0
Interest accrued on Medley Term Loan	640,569	539,719	0
Loss on disposal of assets	70,335	52,862	497,140
Accounts receivable	2,747,827	(2,706,558)	5,065,780
Inventories	(3,156,728)	(9,964,228)	(7,294,767)
Prepaid expenses	1,778,376	(1,036,426)	555,549
Other current and long-term assets	219,495	43,141	352,227
Accounts payable	(6,147,184)	3,412,348	979,698
Accrued expenses and other liabilities	(2,605,224)	2,791,100	(157,397)
Net cash used in operating activities	(20,558,780)	(41,052,374)	(60,352,551)
Purchases of property and equipment	(136,508)	(572,245)	(2,118,183)
Capitalized patents	(567,269)	(795,538)	(1,026,325)
Proceeds from sale of property and equipment	500	449,032	565,918
Net cash used in investing activities	(703,277)	(918,751)	(2,578,590)
Net proceeds (payments) from draws on lines of credit and other short-term borrowings	493,836	(33,842,636)	38,709,705
Proceeds from long-term borrowings	0	29,872,993	0
Payment of short and long-term debt	(64,969)	(17,605)	(4,950)
Debt issuance costs	(338,749)	(3,210,206)	(48,246)
Decrease in restricted cash related to line of credit	0	2,000,000	0
Proceeds from issuance of common stock under equity compensation plans	1,307	6,057	38,998
Fees incurred on issuance of preferred stock	(1,084,403)	(1,169,980)	(658,592)
Net cash provided by financing activities	20,545,022	32,113,623	58,036,915
Effect of exchange rate changes on cash	(244,736)	271,387	255,561
Net decrease in cash	(961,771)	(9,586,115)	(4,638,665)
Cash and cash equivalents balance at beginning of period	1,609,297	11,195,412	15,834,077
Cash and cash equivalents balance at end of period	647,526	1,609,297	11,195,412
Interest paid during the period	5,097,143	4,761,355	3,963,304
Deemed dividends	(20,106,030)	0	$ 0
Fair value of Pegasus Guaranty included in debt issuance costs	$ (3,300,000)	$ (3,200,000)

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1: Description of Business and Basis of Presentation Overview Lighting Science Group Corporation (the “Company”) was incorporated in Delaware in 1988 and designs, develops and markets general illumination products that exclusively use light emitting diodes (“LEDs”) as their light source. The Company’s product portfolio includes LED-based retrofit lamps (replacement bulbs) that can be used in existing light fixtures and sockets as well as purpose built LED-based luminaires (light fixtures) for many common indoor and outdoor residential, commercial, industrial and public infrastructure lighting applications. The Company assembles and manufactures its products through its contract manufacturers in Asia. Basis of Financial Statement Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and the rules of the Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the accompanying consolidated financial statements.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2: Summary of Significant Accounting Policies Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenue and expenses. Such estimates include the valuation of accounts receivable, inventories, intangible assets and other long-lived assets, legal contingencies, and customer incentives, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an on -going basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency and energy markets and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. Foreign Currency Translation The functional currency for the foreign operations of the Company is the local currency of the applicable foreign subsidiary. For the operations of Lighting Science Coöperatief U.A. and Lighting Science Group B.V. (“LSGBV”), the Company’s Netherlands-based subsidiaries, the functional currency is the Euro; for the operations of Lighting Science Group Mexico SRL, (“LSG Mexico”), the Company’s Mexican subsidiary, the functional currency is the Mexican Peso; for the operations of Lighting Science India Private Limited (“LSIPL”), the Company’s Indian subsidiary, the functional currency is the Indian Rupee; for the operations of Lighting Science Group HK Limited (“LSGHK”), the Company’s Hong Kong subsidiary, the functional currency is the Hong Kong Dollar; and for the operations of Lighting Science Group Shenzhen Co., Ltd (“LSGSZ”), the Company’s Chinese subsidiary, the functional currency is the Chinese Yuan Renminbi. The translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and for revenue and expense accounts using the average exchange rate for each period during the year. Any gains or losses resulting from the translation are included in accumulated other comprehensive loss in the consolidated statements of stockholders’ deficit and are excluded from net loss. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. As of both December 31, 2015 and 2014, the Company had no cash equivalents. The Company regularly maintains cash balances in excess of federally insured limits. To date, the Company has not experienced any losses on its cash and cash equivalents. As of December 31, 2015, the Company had $4.2 million in cash and cash equivalents and restricted cash held in banks in the United States in excess of the federally insured limits. Restricted Cash As of December 31, 2015 and 2014, as required by the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company was required to maintain a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. Changes in the restricted cash balance were reflected as a financing activity in the consolidated statements of cash flows. Accounts Receivable The Company records accounts receivable at the invoiced amount when its products are shipped to customers or upon the completion of specific milestone billing requirements. The Company’s receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, aging of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based upon age or customer circumstances that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of December 31, 2015 and 2014, the allowance for doubtful accounts was $475,000 and $408,000, respectively. As of December 31, 2015, $4.2 million of eligible accounts receivable were pledged as collateral for the three-year asset-based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”). First Capital sold the FCC ABL to ACF Finco I LP (“Ares”) in May 2015, and the FCC ABL is hereinafter referred to as the “Ares ABL.” As of December 31, 2014, there were $5.4 million of eligible accounts receivable pledged as collateral for the Ares ABL. Inventories Inventories are stated at the lower of cost or market and have historically consisted of raw materials and purchased components and subsystems, work-in-process and finished lighting products, although inventories currently consist almost exclusively of finished lighting products due to the Company’s transition to contract manufacturers. The Company uses a standard costing methodology, which approximates actual cost on a weighted average basis to value its inventories and the Company reviews its standard costs of raw materials, work-in-process and finished goods inventory on a periodic basis to ensure that its inventories approximate current actual costs. Any purchase price variances related to labor and overhead that would indicate a loss on disposition of inventory is recorded to cost of goods sold in the statement of operations at the end of each reporting period. Market is determined based upon current sales transactions, less the cost of disposal. Work in process and finished lighting products include raw materials, labor and allocated overhead. Significant changes in the Company’s strategic plan, including changes in product mix, product demand, slow product adoption, rapid technological changes and new product introductions and enhancements could result in excess or obsolete inventory. The Company evaluates inventory levels and expected usage on a periodic basis to specifically identify obsolete, slow-moving or non-salable inventory based upon assumptions about future demand and market conditions. The write-down of excess and obsolete inventory based on this evaluation creates a new cost basis and is included in cost of goods sold. On a quarterly basis, the Company considers the need to record a lower of cost or market adjustment for its raw materials and finished goods inventory. The market value of finished goods is determined based upon current sales transactions, less the cost of disposal of the respective finished goods. The write-down of inventory to the lower of cost or market creates a new cost basis that cannot be marked up even if there are subsequent changes in the underlying facts and circumstances. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment under capital leases is stated at the present value of future minimum lease payments. Depreciation is provided using the straight-line method over the estimated economic lives of the assets, as follows: Estimated (years) Leasehold improvements 1 - 5 Office, furniture and equipment 2 - 5 Computer hardware and software 3 - 4 Tooling, production and test equipment 2 - 4 Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the minimum lease term or the estimated useful life of the assets. Expenditures for repairs and maintenance are charged to expense as incurred. The costs for major renewals and improvements are capitalized and depreciated over their estimated useful lives. All costs incurred for building of production tooling and molds are capitalized and amortized over the estimated useful life of the tooling set or mold. Intangible Assets Intangible assets include patents and patents pending. Intangible assets with estimable useful lives are amortized over their respective useful lives on a straight-line basis. Finite–lived intangible assets are reviewed for impairment or obsolescence annually, or more frequently if events or changes in circumstance indicate that the carrying amount of an intangible asset may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows. Impairment of Long-lived Assets Long lived assets, such as property, plant and equipment, and purchased intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third party independent appraisals, as considered necessary. Derivative Instruments The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. All derivatives are recorded at fair value on the consolidated balance sheets and changes in the fair value of such derivatives are measured in each period and are reported in other income (expense). Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Fair Value of Financial Instruments Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates. The Pegasus Commitment (as defined in Note 11 below) and all outstanding warrants other than the THD Warrant (as defined in Note 11 below) were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. The fair value of the THD Warrant is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until they have been earned for each year and these adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot, Inc . (“The Home Depot”). Once a portion of the THD Warrant vests it is recorded at its fair value at the end of each subsequent reporting period. Revenue Recognition The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once these terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims. Shipping and Handling Fees and Costs Shipping and handling fees billed to customers are included in revenue. Shipping and handling costs associated with in-bound freight are included in cost of goods sold. Other shipping and handling costs are included in selling, distribution and administrative expenses and totaled $3.0 million, $1.8 million and $3.4 million for the years ended December 31, 2015, 2014 and 2013, respectively. Research and Development The Company expenses all research and development costs, including amounts for design prototypes and modifications made to existing prototypes, as incurred. Product Warranties The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products and such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The following table summarizes changes in the warranty provision for the years ended December 31, 2015 and 2014 were as follows: Warranty provision as of December 31, 2013 $ 3,231,991 Additions to provision 4,752,626 Less warranty costs (3,195,147 ) Warranty provision as of December 31, 2014 4,789,470 Additions to provision 1,774,786 Less warranty costs (3,278,832 ) Warranty provision as of December 31, 2015 $ 3,285,424 Share Based Compensation The Company recognizes all employee stock based compensation as a cost in the financial statements based on the fair value of the share based compensation award. Equity classified awards are measured at the grant date fair value of the award. The Company estimates grant date fair value using the Black Scholes Merton option pricing model. As of December 31, 2015 and 2014, the Company had two share based compensation plans. The fair value of share based compensation awards, which historically have included stock options and restricted stock awards, is recognized as compensation expense in the statement of operations. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model. Option valuation methods require the input of highly subjective assumptions, including the expected stock price volatility. Measured compensation expense related to such option grants is recognized ratably over the vesting period of the related grants. Restricted stock awards are valued on the date of grant. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in the income tax provision. Advertising Advertising costs are included in selling, distribution and administrative expenses and are expensed when the advertising first takes place. The Company primarily promotes its product lines through print media and trade shows, including trade publications and promotional brochures. Advertising expenses were $43 ,000, $198,000 and $1.3 million for the years ended December 31, 2015, 2014 and 2013, respectively. Segment Reporting The Company operates as a single segment under Accounting Standard Codification (“ASC”) 280-10-50, “Disclosures about Segments of an Enterprise and Related Information”. The Company’s chief operating decision maker reviews financial information at the enterprise level and makes decisions accordingly. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU 2014-09, which will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles and is intended to improve and converge the financial reporting requirements for revenue from contracts with customers with International Financial Reporting Standards (“IFRS”). The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. ASU 2014-09 also requires additional disclosures about the nature, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. ASU 2014-09 allows for both retrospective and prospective methods of adoption and is effective for periods beginning after December 15, 2016. In August 2015, the FASB issued ASU 2015-14 which provides a one-year deferral of the revenue recognition standard’s effective date. Public business entities are required to apply the revenue recognition standard to annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. Early application is permitted but not before the original effective date for public business entities (annual reporting periods beginning after December 15, 2016). The option to use either a retrospective or cumulative-effective transition method did not change. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2014-09 will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15 requiring management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. The standard also provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new guidance is effective for the annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2014-15 will have on its consolidated financial statements. In April 2015, the FASB issued ASU 2015-03 that intends to simplify the presentation of debt issuance costs. The new standard will more closely align the presentation of debt issuance costs under U.S. generally accepted accounting principles with the presentation under comparable IFRS standards. Debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. ASU 2015-03 is effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. The cost of issuing debt will no longer be recorded as a separate asset, except when incurred before receipt of the funding from the associated debt liability. Under current U.S. generally accepted accounting principles, debt issuance costs are reported on the balance sheet as assets and amortized as interest expense. The costs will continue to be amortized to interest expense using the effective interest method. Subsequent to the issuance of ASU 2015-03 the Securities and Exchange Commission staff made an announcement regarding the presentation of debt issuance costs associated with line-of-credit arrangements, which was codified by the FASB in ASU 2015-15. This guidance, which clarifies the exclusion of line-of-credit arrangements from the scope of ASU 2015-03, is effective upon adoption of ASU 2015-03. The Company has adopted both ASU 2015-03 and 2015-15. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2015-03 will have on its consolidated financial statements. In November 2015, the FASB issued ASU No 2015-17 to simplify the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in the balance sheet. The new guidance is effective for the annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2015-17 will have on its consolidated financial statements.

Note 3 - Liquidity and Capital

Note 3 - Liquidity and Capital Resources	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Liquidity and Capital Resources [Text Block]	Note 3: Liquidity and Capital Resources As shown in the consolidated financial statements, the Company has experienced significant historical net losses as well as negative cash flows from operations since its inception, resulting in an accumulated deficit of $827.4 million and stockholders’ deficit of $551.4 million as of December 31, 2015. As of December 31, 2015, the Company had cash and cash equivalents of $648,000 and an additional $3.0 million in restricted cash subject to a cash collateral dominion agreement pursuant to the Medley Term Loan. The Company’s cash expenditures primarily relate to procurement of inventory, payment of salaries, employee benefits and other operating costs. The Company’s primary sources of liquidity have historically been borrowings from Ares under the Ares ABL, from Medley under the Medley Term Loan and from other previous lenders, as well as sales of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and Convertible Preferred Stock (as defined below) to, and short-term loans from, affiliates of Pegasus Capital Advisors, L.P. (“Pegasus Capital”), including Pegasus Partners IV, L.P. (“Pegasus Fund IV”), LSGC Holdings, LLC (“LSGC Holdings”), LSGC Holdings II, LLC (“Holdings II”), LSGC Holdings III, LLC (“Holdings III”) and PCA LSG Holdings, LLC (“PCA Holdings” and collectively with Pegasus Capital, Pegasus Fund IV, LSGC Holdings, Holdings II, Holdings III and their affiliates, “Pegasus”). Pegasus is the Company’s controlling stockholder. While Pegasus has led a majority of the Company’s capital raises, certain offerings of Convertible Preferred Stock also involved and/or were led by parties other than Pegasus. The Company obtained the five-year, $30.5 million Medley Term Loan from Medley on February 19, 2014, pursuant to a Term Loan Agreement (as amended from time to time the “Medley Loan Agreement”). Pursuant to the Medley Loan Agreement, the Company is required to achieve a minimum quarterly fixed charge coverage ratio for the preceding 12-month period and to maintain certain minimum EBITDA levels. In connection with the Medley Term Loan, the Company issued a warrant to purchase 5,000,000 shares of Common Stock to each of Medley and Medley Opportunity Fund II LP (the “Medley Warrants”). The Company also obtained a three-year revolving credit facility with a maximum line amount of $22.5 million from Ares on April 25, 2014, pursuant to a Loan and Security Agreement (as amended from time to time, the “Ares ABL Agreement”). As of December 31, 2015, the Company had $6.9 million in borrowings outstanding under the Ares ABL Agreement and additional borrowing capacity of $6.3 million. The maximum borrowing capacity under the Ares ABL Agreement is based on a formula of eligible accounts receivable and inventory. The Ares ABL Agreement also requires the Company to achieve a minimum quarterly fixed charge coverage ratio for the preceding 12-month period. On January 30, 2015 and September 11, 2015 , the Company issued 11,525 and 10,000 units of its securities (“Series J Securities”), respectively, to Holdings III. On September 30, 2015, the Company issued 62 Series J Securities to certain existing preferred stockholders upon exercise of their preemptive rights under the certificates of designation governing the Convertible Preferred Stock. In each case, the Series J Securities were issued at a purchase price of $1,000 per Series J Security, and the Company received aggregate gross proceeds of approximately $21.6 million in connection with these issuances. Each Series J Security consists of (i) one share of Series J Convertible Preferred Stock (“Series J Preferred Stock”) and (ii) a warrant to purchase 2,650 shares of Common Stock, at an exercise price of $0.001 per share (the “Series J Warrants”). The Company continues to face challenges in its efforts to achieve profitability and positive cash flows from operations. The Company’s ability to continue to meet its obligations in the ordinary course of business is dependent upon establishing profitable operations, which may be supplemented by any additional funds that the Company may raise through public or private financing or increased borrowing capacity. In 2015 , the Company’s largest customer, The Home Depot, performed a periodic product line review relating to its entire private label LED lighting product offering. Following the line review, the Company entered into a new supplier buying agreement with The Home Depot, which is expected to go into full effect in April or May 2016. Pursuant to this new supplier buying agreement, The Home Depot has elected to purchase certain products previously supplied by the Company directly from overseas suppliers. Such products represented a significant percentage of the Company’s sales to The Home Depot in 2015 and 2014. The Company was, however, selected to supply certain new products to The Home Depot and will continue to supply certain other products to The Home Depot under its prior agreement. In addition, the terms of the new supplier buying agreement with The Home Depot permit the Company to pursue opportunities to sell products to specified big box and other retailers, which was prohibited under its prior agreement. Notwithstanding the new supplier buying agreement, as was the case under the Company’s prior agreement with The Home Depot, The Home Depot is not required to purchase any minimum amount of products from the Company. As a result of the line review, the Company expects 2016 sales to The Home Depot and, as a result, revenue, to be significantly less than what it was in 2015. However, because the Company cannot reasonably estimate the extent to which such reduced revenue may be offset by sales of the new products to The Home Depot or by any potential new sales to other retailers, the Company cannot determine at this time the overall impact that the results of The Home Depot line review will have on the Company’s financial condition and operations in the future. As a result of the Company’s historical losses, the Company believes it will likely need to raise additional capital to fund its operations. Sources of additional capital may not be available in an amount or on terms that are acceptable to the Company, if at all. The Company’s complex capital structure, including its obligations to the holders of the outstanding shares of its Convertible Preferred Stock and the new series of preferred stock designated as Series K (“Series K Preferred Stock”), may make it more difficult to raise additional capital from new or existing investors or lenders. If the Company is not able to raise such additional capital, the Company may need to restructure or refinance its existing obligations, which restructuring or refinancing would require the consent and cooperation of the Company’s creditors and certain stockholders. In such event, the Company may not be able to complete a restructuring or refinancing on terms that are acceptable to the Company, if at all. If the Company is unable to obtain sufficient capital when needed, the Company’s business, compliance with its credit facilities and future prospects may be adversely affected. Pegasus has committed to provide financial support to the Company of up to $5.25 million, as needed, to fund its operations and debt service requirements for at least the next 12 months. The amount of this commitment will be reduced by amounts funded by other parties (except for draws under the Ares ABL) within the next 12 months that are not repayable by the Company on or before April 14, 2017. Such commitment, which in no way amounts to a guarantee of the Company’s obligations, may be provided through a variety of mechanisms, which may or may not be similar to those previously employed. Furthermore, in exchange for such support, Pegasus, as the Company’s controlling stockholder, may request that the Company take certain actions related to operations, capital structure or otherwise, which, if accepted, could have a negative effect on its business and results of operations. In addition, Pegasus may seek other terms and consideration that would require, and may not receive, approval by the independent committee of the Company’s board of directors. Management believes that, subject to certain conditions, the Company will have sufficient capital to fund its operations for the next 12 months. Such conditions include, among other things, (1) maintaining the Company’s lower cost structure implemented over the last three years, (2) replacing a significant portion of the decline in revenue anticipated as a result of The Home Depot’s line review and (3) if necessary, Pegasus fulfilling its commitment as described above. RW LSG Holdings LLC (“Riverwood Holdings”) and Pegasus each have the right to cause the Company to redeem their shares of Series H Convertible Preferred Stock (“Series H Preferred Stock”) and Series I Convertible Preferred Stock (“Series I Preferred Stock” and, collectively with the Series H Preferred Stock and the Series J Preferred Stock, the “Convertible Preferred Stock”), respectively, at any time on or after March 27, 2017. If either Riverwood Holdings or Pegasus elects to cause the Company to redeem its shares of Series H Preferred Stock or Series I Preferred Stock, all other holders of the applicable series will similarly have the right to request the redemption of their shares of Convertible Preferred Stock. In addition, Portman Limited (“Portman”) and affiliates of Zouk Holdings Limited, acting together, have a contractual right to require the Company to redeem their respective shares of Series H Preferred Stock on or after March 27, 2017, subject to certain conditions and limitations. The Company is also required to redeem the outstanding shares of its Series J Preferred Stock (a) subject to certain limited exceptions, immediately prior to the redemption of the Series H Preferred Stock, Series I Preferred Stock or any other security that ranks junior to the Series J Preferred Stock and (b) on November 14, 2019, at the election of the holders of Series J Preferred Stock (a “Special Redemption”). Holders of Convertible Preferred Stock would also have the right to require the Company to redeem such shares upon the uncured material breach of the Company’s obligations under its outstanding indebtedness or the uncured material breach of the terms of the certificates of designation governing the Convertible Preferred Stock. Depending on whether the Appeal Bond (as defined below) has been drawn or fully released, the Series K Certificate of Designation requires us to redeem the outstanding shares of Series K Preferred Stock in the event of a liquidation, dissolution or winding up of the Company or an earlier change of control or “junior security redemption,” which includes events triggering a redemption of the outstanding shares of Convertible Preferred Stock. As of December 31, 2015, in the event the Company was required to redeem all of its outstanding shares of Convertible Preferred Stock and Series K Preferred Stock (collectively, the “Preferred Stock”), the Company’s maximum payment obligation would have been $532.2 million. The Company would be required to repay its outstanding obligations under the Medley Term Loan and the Ares ABL prior to the redemption of any shares of Preferred Stock. As of December 31, 2015, the Company had $36.1 million of aggregate borrowings outstanding under these credit facilities that the Company would be required to repay. Any redemption of the Preferred Stock would be limited to funds legally available therefor under Delaware law. The certificates of designation governing the Preferred Stock provide that if there is not a sufficient amount of cash or surplus available to pay for a redemption of Preferred Stock, then the redemption must be paid out of the remaining assets of the Company. In addition, the certificates of designation governing the Preferred Stock provide that the Company is not permitted or required to redeem any shares of Preferred Stock for so long as such redemption would result in an event of default under the Company’s credit facilities. As of December 31, 2015, based solely on a review of the Company’s balance sheet, the Company did not have legally available funds under Delaware law to satisfy a redemption of its Preferred Stock. In addition, based solely on the Company’s projected balance sheet as of March 27, 2017, the Company does not believe that it will have legally available funds on or before March 27, 2017 to satisfy any such redemption of the Preferred Stock. The certificate of designation governing the Series H Preferred Stock also provides that upon the occurrence of a “control event,” the Company must take any and all actions required and permitted to fix the size of its board of directors to a size that would permit Riverwood Holdings (as the primary investor of the Series H Preferred Stock) to appoint a majority of the directors to the board until the Company satisfies or otherwise cures the obligations giving rise to the control event. A control event occurs if, among other things, Riverwood Holdings exercises its optional redemption right under the certificate of designation governing the Series H Preferred Stock and the Company is unable to redeem Riverwood Holdings’ shares of Series H Preferred Stock. If Riverwood Holdings were to exercise its optional redemption right and a control event were to occur, Riverwood Holdings could take control of the board of directors. The certificate of designation governing the Series J Preferred Stock provides that if the Company does not have sufficient capital available to redeem the Series J Preferred Stock in connection with a Special Redemption of the Series J Preferred Stock, the Company will be required to issue a non-interest bearing note or notes (payable 180 days after issuance) in the principal amount of the liquidation amount of any shares of Series J Preferred Stock not redeemed by the Company in connection with such Special Redemption, subject to certain limitations imposed by Delaware law governing distributions to stockholders. As discussed further in Note 8, one of the Company’s stockholders, Geveran Investments Limited (“Geveran”), filed a lawsuit against the Company and certain other defendants seeking, among other things, rescissionary damages in connection with its $25.0 million investment in the Company. On November 30, 2015, the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, the court presiding over the lawsuit, entered an Order Granting Plaintiff’s Motion for Partial Summary Judgment Under its First Cause of Action for Violation of the Florida Securities and Investment Protection Act (the “Summary Judgment Order”). Accordingly, the Company, with the assistance of Pegasus Fund IV, posted an appeal bond in the amount of $20.1 million (the “Appeal Bond”) in support of the Company’s appeal of the Summary Judgment Order. As contemplated by the Preferred Stock Subscription and Support Agreement dated September 11, 2015 (the “Subscription and Support Agreement”) among the Company, Holdings III and Pegasus Partners IV, L.P. (“Pegasus Fund IV”), Pegasus Fund IV agreed to assist the Company in securing the Appeal Bond on the terms set forth in a General Indemnity Agreement and related side letter to be entered into by and among the Company, Pegasus Fund IV and the issuer of the Appeal Bond (the “Appeal Bond Agreements”). The Company executed the Appeal Bond Agreements with Pegasus Fund IV and the issuer of the Appeal Bond on December 4, 2015, and on December 7, 2015, in consideration of Pegasus Fund IV’s entry into the Appeal Bond Agreements and as security for the potential payments to be made to the issuer of the Appeal Bond for draws upon the Appeal Bond, the Company issued 20,106.03 units of its securities (the “Series K Securities”) to Pegasus Fund IV pursuant to the Subscription and Support Agreement, with each Series K Security consisting of (a) one share of Series K Preferred Stock and (b) a warrant to purchase 735 shares of Common Stock (a “Series K Warrant”). The number of Series K Securities issued to Pegasus Fund IV was determined based on the quotient obtained by dividing (x) the aggregate amount of the bonds, undertakings, guarantees and/or contractual obligations underlying Pegasus Fund IV’s initial commitment with respect to the Appeal Bond by (y) $1,000. Although the Company cannot predict the ultimate outcome of this lawsuit, it believes the court’s summary judgment award in favor of Geveran is in error and that it has strong defenses against Geveran’s claims. However, in the event that the Company is not successful on appeal, it could be liable for the full amount of Geveran’s $25.0 million investment, as well as interest, attorneys’ fees and court costs. Accordingly, the Summary Judgment Order and the Appeal Bond could have a material adverse effect on the Company’s liquidity and its ability to raise capital in the future.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4: Fair Value Measurements The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015, according to the valuation techniques the Company used to determine their fair values: Fair Value Measurement as of Decmber 31, 2015 Quoted Price in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 Assets (Recurring): Pegasus Commitment (1) $ - $ - $ 214,400 Liabilities (Recurring): Riverwood Warrants (2) $ - $ - $ 1,747,737 September 2012 Warrants (3) - - 214,400 Pegasus Warrant - - 966,000 THD Warrant - - 63,635 Medley Warrants - - 565,776 Pegasus Guaranty Warrants - - 615,261 $ - $ - $ 4,172,809 (1) On September 25, 2012, the Company entered into a Commitment Agreement with Pegasus Fund IV, pursuant to which the Company is obligated to buy from Pegasus Fund IV or its affiliates shares of Common Stock equal to the number of shares, if any, for which the September 2012 Warrants (as defined below) are exercised, up to an aggregate number of shares of Common Stock equal to the aggregate number of shares of Common Stock underlying all of the September 2012 Warrants. (2) On May 25, 2012, the Company issued a warrant to purchase 18,092,511 shares of Common Stock to Riverwood Management as consideration for services provided in connection with an offering of Convertible Preferred Stock (the “Riverwood Warrant”). Riverwood Management has since partially assigned such warrant to several of its affiliates. The warrants, as amended or assigned from time to time, are referred to herein as the “Riverwood Warrants.” (3) In September 2012, in connection with an offering of Convertible Preferred Stock, the Company issued warrants to purchase an aggregate of 8,000,000 shares of Common Stock (the “September 2012 Warrants”) to Portman, Cleantech Europe II (A) L.P. (“Cleantech A” and Cleantech Europe II (B) L.P. (Cleantech B” and together with Cleantech A, “Zouk”). The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs as defined above for the year ended December 31, 2015: Realized and unrealized Purchases, Balance gains (losses) sales, Transfers in Balance December 31, included issuances and or out of December 31, 2014 in net loss settlements Level 3 2015 Pegasus Commitment $ 720,000 $ (505,600 ) $ - $ - $ 214,400 Riverwood Warrants (2,352,027 ) 604,290 - - (1,747,737 ) September 2012 Warrants (720,000 ) 505,600 - - (214,400 ) Pegasus Warrant (1,300,000 ) 334,000 - - (966,000 ) THD Warrant (43,928 ) (19,707 ) - - (63,635 ) Medley Warrants (577,065 ) 11,289 - - (565,776 ) Pegasus Guaranty Warrants (643,924 ) 28,663 - - (615,261 ) Total $ (4,916,944 ) $ 958,535 $ - $ - $ (3,958,409 ) The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs as defined above for the year ended December 31, 2014: Realized and unrealized Purchases, Balance gains (losses) sales, Transfers in Balance December 31, included issuances and or out of December 31, 2013 in net loss settlements Level 3 2014 Pegasus Commitment $ 1,407,335 $ (687,335 ) $ - $ - $ 720,000 Riverwood Warrants (5,002,664 ) 2,650,637 - - (2,352,027 ) September 2012 Warrants (1,407,335 ) 687,335 - - (720,000 ) Pegasus Warrant (2,765,047 ) 1,465,047 - - (1,300,000 ) THD Warrant - 30,648 - (74,576 ) (43,928 ) Series J Warrants - (25,140,561 ) (12,505,739 ) 37,646,300 - Medley Warrants - 2,593,296 (3,170,361 ) - (577,065 ) Pegasus Guaranty Warrants - 2,692,650 (3,336,574 ) - (643,924 ) Total $ (7,767,711 ) $ (15,708,283 ) $ (19,012,674 ) $ 37,571,724 $ (4,916,944 )

Note 5 - Inventories

Note 5 - Inventories	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 5: Inventories Inventories consisted primarily of finished goods as of December 31, 2015 and December 31, 2014. On a quarterly basis, the Company performs a review of its inventory for estimated obsolete or slow-moving inventory based upon assumptions about future demand and market conditions. As a result of these reviews, the Company recorded an inventory write-down of $3.6 million, $4.7 million and $11.4 million for the years ended December 31, 2015, 2014 and 2013, respectively, with the expense included in cost of goods sold. As of December 31, 2015 and December 31, 2014, inventories are stated net of inventory reserves of $6.9 million and $7.9 million, respectively. The Company considered a number of factors in estimating the required inventory reserves, including (i) the focus of the business on the next generation of the Company’s products, which utilize lower cost technologies, (ii) the strategic focus on core products to meet the demands of key customers and (iii) the expected demand for the Company’s current generation of products, which are approaching the end of their lifecycle upon the introduction of the next generation of products. During the years ended December 31, 2015, 2014 and 2013, the Company recorded $116,000, $507,000 and $2.3 million, respectively, in provisions for losses on non-cancellable purchase commitments of which $0 and $540,000 were accrued as of December 31, 2015 and 2014, respectively, which were included in cost of goods sold in the consolidated statements of operations .

Note 6 - Property and Equipment

Note 6 - Property and Equipment	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 6: Property and Equipment Property and equipment consists of the following: December 31, 2015 December 31, 2014 Leasehold improvements $ 171,808 $ 158,421 Office furniture and equipment 290,348 293,183 Computer hardware and software 7,878,439 7,876,262 Tooling, production and test equipment 4,219,956 4,559,942 Trailers 45,996 45,996 Construction-in-process - 45,817 Total property and equipment 12,606,547 12,979,621 Accumulated depreciation (11,749,857 ) (10,329,506 ) Total property and equipment, net $ 856,690 $ 2,650,115 Depreciation related to property and equipment was $1.9 million, $3.3 million and $8.7 million for the years ended December 31, 2015, 2014 and 2013, respectively. Impairment of Property and Equipment Property and equipment are depreciated over their estimated economic lives. Long-lived assets, including property and equipment, are evaluated to determine whether, in management’s judgment, events or changes in circumstances have occurred that may warrant a revision of the estimated useful life or whether the remaining balance should be evaluated for possible impairment. Such impairment tests compare estimated undiscounted cash flows over the remaining life of the property and equipment in assessing whether an asset has been impaired. If an impairment is indicated, the asset is written down to its fair value based on an estimate of its discounted cash flows. For the year ended December 31, 2015, there were no impairment charges for property and equipment. In September and December 2014, the Company performed an impairment analysis of property and equipment related to its Melbourne, Florida headquarters, in connection with the transition of a majority of the Company’s manufacturing operations to its contract manufacturers in Asia. This impairment analysis included an assessment of the proposed future use of the property and equipment and their estimated useful lives. As a result of this assessment the Company recorded an impairment charge of $637,000 for the year ended December 31, 2014, which is included in restructuring expense. In November and December 2013, the Company performed an impairment analysis of property and equipment related to its Satellite Beach, Florida headquarters, its facility in The Netherlands, operated by its subsidiary LSGBV, and its facility in India , operated by its subsidiary LSIPL, in connection with the transition of a majority of the Company’s manufacturing operations to its contract manufacturers in Asia and the winding down of business in the Netherlands and India. This impairment analysis included an assessment of the proposed future use of the property and equipment and their estimated useful lives. As a result of this assessment the Company recorded an impairment charge of $2.4 million for the year ended December 31, 2013, which is included in restructuring expense.

Note 7 - Intangible Assets and

Note 7 - Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 7: Intangible Assets and Goodwill Intangible assets that have finite lives are amortized over their useful lives. The intangible assets, their original fair values, adjusted for impairment charges, and their net book values are detailed below as of the dates presented: Cost, Less I mpairment Charges Accumulated Amortization Net Book Value Estimated Remaining Useful Life (years) December 31, 2015: Technology and intellectual property $ 3,332,556 $ (307,662 ) $ 3,024,894 0.9 to 20.0 December 31, 2014: Technology and intellectual property $ 2,796,580 $ (224,101 ) $ 2,572,479 2.7 to 20.0 Total intangible amortization expense was $84,000, $64,000 and $40,000 for the years ended December 31, 2015, 2014 and 2013, respectively. The table below is the estimated amortization expense, adjusted for any impairment charges, for the Company’s intangible assets for each of the next five years and thereafter: 2016 $ 98,560 2017 98,560 2018 98,560 2019 98,560 2020 98,560 Thereafter 2,532,094 $ 3,024,894 Impairment of Intangible Assets Intangible assets with estimable useful lives are amortized over their respective useful lives to their estimated residual values, and reviewed to determine if their estimable lives have decreased. Long-lived assets, including intangible assets subject to amortization, are reviewed for impairment whenever, in management’s judgment, conditions indicate a possible impairment. Such impairment tests compare estimated undiscounted cash flows to the carrying value of the asset. If an impairment is indicated, the asset is written down to its fair value based on an estimate of its discounted cash flows. During the years ended December 31, 2015, 2014 and 2013, there were no impairment charges for intangible assets.

Note 8 - Debt Issuance Costs

Note 8 - Debt Issuance Costs	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Debt Issuance Costs [Text Block]	Note 8 . Debt Issuance Costs The Company capitalizes its costs related to the issuance of long-term debt and amortizes these costs using the effective interest rate method over the life of the loan. Amortization of debt issuance costs and the accelerated write-off of debt issuance costs in connection with refinancing activities are recorded as a component of interest expense. The Company had net debt issuance costs of $3.3 million and $3.2 million as of December 31, 2015 and 2014, respectively. As of December 31, 2015, the current portion of the debt issuance costs was $1.8 million and was included in other current assets. In connection with the Ares ABL and the Medley Term Loan, $6.0 million of debt issuance costs were capitalized, including $2.8 million related to the fair value of the Pegasus Guaranty (as defined in Note 9 below). The Company amortized $1.5 million, $1.6 million and $507,000 of debt issuance costs for the years ended December 31, 2015, 2014 and 2013, respectively.

Note 9 - Lines of Credit and No

Note 9 - Lines of Credit and Note Payable	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 9: Lines of Credit and Note Payable Ares ABL On April 25, 2014, the Company, entered into the Ares ABL, which provides the Company with a maximum borrowing capacity of $22.5 million, calculated based on a formula of eligible accounts receivable and inventory. As of December 31, 2015, the Company had $6.9 million outstanding under the Ares ABL and additional borrowing capacity of $6.3 million. On September 11, 2015, the Company entered into an amendment to the Ares ABL, which among other things (i) increased the interest margin payable under the Ares ABL by 150 basis points, such that the interest accrues on the outstanding borrowings at a rate equal to LIBOR plus 5.5%, (ii) provided for a mandatory repayment in full of the obligations under the Ares ABL if the Company redeems the Series K Preferred Stock, (iii) allowed the Company to enter into the Appeal Bond and certain related agreements without further consent or approval from Ares, (iv) provided that the Company must notify Ares of entry of the Summary Judgment Order within two business days of the entry thereof, and (v) added certain events of default relating to the Geveran litigation. As of December 31, 2015, eligible collateral included $3.5 million of accounts receivable and $10.0 million of inventory. Borrowings under the Ares ABL bear interest at a floating rate equal to one-month LIBOR plus 5.5% per annum. As of December 31, 2015, the interest rate on the Ares ABL was 5.74%. The Ares ABL matures on April 25, 2017. Medley Delayed Draw Loan On February 19, 2014, the Company entered into the Medley Delayed Draw Loan, which provided the Company with borrowing capacity of up to $22.5 million. The Medley Delayed Draw Loan bore interest at a floating rate equal to three-month LIBOR plus 10.5% per annum. Proceeds from the Ares ABL were used to repay the Company’s outstanding obligations under the Medley Delayed Draw Loan on April 25, 2014. Medley Term Loan On February 19, 2014, the Company entered into the Medley Term Loan, which provided the Company with a $30.5 million term loan facility. The Medley Term Loan bears interest at a floating rate equal to three-month LIBOR plus 12% per annum, as follows: (i) up to 2% (at the Company’s election) of interest may be paid as “payment in kind” by adding such accrued interest to the unpaid principal balance of the Medley Term Loan and (ii) the remaining accrued interest amount is payable in cash monthly in arrears. As of December 31, 2015, the interest rate on the Medley Term Loan was 12.41%. Additionally, $3.0 million of the Medley Term Loan was funded directly into a deposit account to which Medley has exclusive access, to further secure the loan. This $3.0 million is recorded as restricted cash in the accompanying consolidated balance sheets. The outstanding principal balance and all accrued and unpaid interest on the Medley Term Loan are due and payable on February 19, 2019. Activity in the Medley Term Loan for the years ended December 31, 2015 and 2014 is set forth below: Borrowing, February 19, 2014 $ 30,500,000 Discount for Warrants (3,170,361 ) Discount for Commitment Fees (725,000 ) Accretion - Discounts 668,703 Paid in Kind - Interest Accretion 539,719 Balance, December 31, 2014 27,813,061 Accretion - Discounts 779,072 Paid in Kind - Interest Accretion 640,569 Balance, December 31, 2015 $ 29,232,702 For the years ended December 31, 2015 and 2014, the Company recognized $779,072 and $668,703, respectively, of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants. In addition, the Company also recognized $640,569 and $539,719, respectively, of accrued interest for the years ended December 31, 2015 and 2014. On September 11, 2015, the Company entered into an amendment to the Medley Term Loan, which among other things, (i) amended the minimum EBITDA covenant levels with respect to each of the 12-month period ended September 30, 2015, the 12-month period ending December 31, 2015, the 12-month period ending March 31, 2016 and the 12-month period ending June 30, 2016 (collectively, the “Specified Covenant Periods ”) to provide that a portion of the cash proceeds from the sale of Series J Securities on September 11, 2015 will be included in the calculation of EBITDA for such periods, (ii) amended the definition of “Fixed Charge Coverage Ratio” in the Medley Term Loan Agreement to provide that $10.0 million of the cash proceeds from the September 11, 2015 offering will be included in EBITDA for purposes of calculating the “Fixed Charge Coverage Ratio” for each of the Specified Covenant Periods, (iii) allowed the Company to enter into the Appeal Bond and certain related agreements without further consent or approval from Medley and (iv) added certain events of default relating to the Geveran litigation. Medley Warrants On February 19, 2014, in connection with the Medley Loan Agreement, the Company issued the Medley Warrants to Medley and Medley Opportunity Fund II LP, each of which represents the right to purchase 5,000,000 shares of Common Stock. The Medley Warrants have an exercise price equal to $0.95 and, if unexercised, expire on February 19, 2024. The Medley Warrants became exercisable on April 14, 2014. The Medley Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the down round protection provided to the holders by the instruments. The Medley Warrants were recorded as a liability at fair value using the Black Scholes valuation method at issuance and were valued at $3.2 million as of February 19, 2014, which was recorded as a discount to the Medley Term Loan. The discount is being accreted using the effective interest rate method over the life of the loan as a non-cash charge to interest expense. Changes in the fair value of the Medley Warrants are measured and recorded at the end of each quarter. The decrease in fair value of the Medley Warrants was $11,000 and $2.6 million for the years ended December 31, 2015 and 2014, respectively, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statements of operations and comprehensive loss. Accretion of the discount on the Medley Term Loan was $640,569 and $539,719 for the years ended December 31, 2015 and 2014, respectively, and was included in interest expense. On February 19, 2014, the Company also entered into a registration rights agreement with Medley and Medley Opportunity Fund II LP, pursuant to which the Company granted piggyback registration rights with respect to the shares of Common Stock underlying the Medley Warrants and any other shares of Common Stock that may be acquired by such parties in the future. Pegasus Guaranty and Pegasus Guaranty Warrants Pegasus Capital Partners IV, L.P. and Pegasus Capital Partners V, L.P. (collectively, the “Pegasus Guarantors”) agreed to provide a guaranty of the Company’s obligations under the Medley Loan Agreement in favor of Medley (the “Pegasus Guaranty”). The Pegasus Guaranty was recorded as debt issuance costs at fair value on the date of issuance. The fair value was determined to be $2.8 million as of February 19, 2014, using an implied interest rate analysis. The debt issuance costs will be amortized as non-cash interest expense over the life of the Medley Term Loan. As consideration for the Pegasus Guaranty, on February 19, 2014, the Company issued a warrant to purchase 5,000,000 shares of Common Stock to each of the Pegasus Guarantors (the “Pegasus Guaranty Warrants”). The Pegasus Guaranty Warrants have an exercise price equal to $0.50 and, if unexercised, expire on February 19, 2024. The Pegasus Guaranty Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging,” due to the down round protection provided by the instrument. The Pegasus Guaranty Warrants were recorded as a liability at fair value using the Black Scholes valuation method at issuance and were valued at $3.3 million at February 19, 2014. The fair value of the Pegasus Guaranty was $2.8 million at February 19, 2014 and partially offset the fair value of the Pegasus Guaranty Warrants, with the remaining value of $571,000 accounted for as a deemed dividend to the Company’s controlling stockholder. Changes in the fair value of the Pegasus Guaranty Warrants are measured and recorded at the end of each quarter. The decrease in fair value of the Pegasus Guaranty Warrants was $29,000 and $2.7 million for the years ended December 31, 2015 and 2014, respectively, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss. Wells Fargo The Company’s previous asset-based lending facility with Wells Fargo Bank, N.A. (“Wells Fargo”) provided the Company with borrowing capacity of up to $50.0 million (the “Wells Fargo ABL”). On February 19, 2014, the Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Wells Fargo ABL. Ares Capital Corporation On September 21, 2011, the Company entered into a $25.0 million standby letter of credit issued by Ares Capital Corporation in favor of Wells Fargo for the benefit of the Company (the “Ares Letter of Credit Facility”) . On February 19, 2014, the Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Ares Letter of Credit Facility.

Note 10 - Redeemable Preferred

Note 10 - Redeemable Preferred Stock	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Redeemable and Convertible Preferred Stock [Text Block]	Note 10: Redeemable Preferred Stock In 2012, the Company issued an aggregate of 60,705 shares of Series H Preferred Stock and 6,364 shares of Series I Preferred Stock to Riverwood Holdings, an affiliate of Riverwood LSG Management Holdings LLC (“Riverwood Management”) and Riverwood Capital Partners L.P. (“Riverwood Capital,” and collectively with Riverwood Holdings, Riverwood Management and their affiliates, “Riverwood”) and certain other accredited investors. On September 11, 2013, in connection with an offering of Series J Preferred Stock described below, Riverwood and Pegasus, as the “Primary Investors” of the Series H Preferred Stock and Series I Preferred Stock, respectively, approved amended and restated certificates of designation governing the Series H Preferred Stock and Series I Preferred Stock and certain holders of shares of Series H Preferred Stock and Series I Preferred Stock agreed to make certain amendments to the preferred stock subscription agreements entered into in connection with previous issuances of shares of the Company’s preferred stock, including shares of Series H Preferred Stock and Series I Preferred Stock. Pursuant to such amended and restated certificates of designation, the terms of the Series H Preferred Stock and Series I Preferred Stock were amended to, among other things, (i) reduce the price used to determine the number of shares of Common Stock each share of Series H Preferred Stock and Series I Preferred Stock can be converted into at the election of each holder from $1.18 to $0.95 (the “Conversion Price”); (ii) remove the covenant requiring the Company to comply with certain minimum thresholds related to the Company’s consolidated earnings before interest, taxes, depreciation and amortization for 2013 and 2014; (iii) increase, from $10 million to $50 million, the amount of indebtedness the Company can incur without the consent of Riverwood and Pegasus (in each case, in their capacity as “Primary Investor” of the Series H Preferred Stock and Series I Preferred Stock, respectively) and (iv) make certain other clarifying amendments to the certificates of designation. The outstanding shares of Series H Preferred Stock and Series I Preferred Stock are entitled to dividends of the same type as any dividends or other distribution of any kind payable or to be made on outstanding shares of Common Stock, on an as converted basis. Each share of Series H Preferred Stock or Series I Preferred Stock is convertible at any time, at the election of the holder thereof, into the Optional Conversion Shares equal to the quotient obtained by dividing (a) the $1,000 by (b) the $0.95 conversion price, subject to certain adjustments. As described in Note 3, Riverwood and Pegasus each have the right to cause the Company to redeem their shares of Series H Preferred Stock and Series I Preferred Stock, respectively, at any time on or after March 27, 2017. If either Riverwood or Pegasus elects to cause the Company to redeem its shares of Series H Preferred Stock or Series I Preferred Stock, all other holders of the applicable series will similarly have the right to request the redemption of their shares of Convertible Preferred Stock. In addition, Portman and affiliates of Zouk, acting together, have a contractual right to require the Company to redeem their respective shares of Series H Preferred Stock on or after March 27, 2017, subject to certain conditions and limitations. In connection with a reduction in the Conversion Price for the Series H Preferred Stock and the Series I Preferred Stock in 2013, the Company recorded a deemed dividend of $14.4 million, which was reflected in earnings per share allocated to controlling stockholders and noncontrolling stockholders. The Series J Preferred Stock is senior to the Series H Preferred Stock, the Series I Preferred Stock and the Common Stock and is entitled to dividends of the same type as any dividends or other distribution of any kind payable or to be made on outstanding shares of Common Stock, on an as converted basis. Each share of Series J Preferred Stock is convertible at any time, at the election of the holder thereof, into the number of shares of Common Stock (the “Optional Conversion Shares”) equal to the quotient obtained by dividing (a) the stated value of such shares of Series J Preferred Stock, which is $1,000 (subject to adjustment, the “Stated Value”) by (b) the $0.95 conversion price, subject to certain adjustments. The Company is required to redeem all outstanding shares of the Series J Preferred Stock for an amount in cash equal to the Liquidation Amount (as defined below) (a) subject to certain limited exceptions, immediately prior to the redemption of a Junior Security; (b) on November 14, 2019, as the Special Redemption; and (c) upon the occurrence of an uncured material breach by the Company of any of the certificates of designation governing the Convertible Preferred Stock. If the Company does not have sufficient capital available to redeem the Series J Preferred Stock upon the exercise of a Special Redemption, the Company will be required to issue a non-interest bearing note or notes (payable 180 days after issuance) in the principal amount of the liquidation amount of any shares of Series J Preferred Stock not redeemed by the Company in connection with such Special Redemption, subject to certain limitations imposed by Delaware law governing distributions to stockholders. The redemption of any shares of Series J Preferred Stock would be senior and prior to any redemption of any Junior Security. Any holder of shares of Series J Preferred Stock may elect to have less than all or none of such holder’s shares of Series J Preferred Stock redeemed. At any time after the Company has redeemed any shares of any Junior Security each holder of shares of Series J Preferred Stock may elect to have all or a portion of such holder’s shares of Series J Preferred Stock redeemed by the Company for an amount in cash equal to the Liquidation Amount of such shares of Series J Preferred Stock. The “Liquidation Amount” of each share of Series J Preferred Stock is equal to the greater of (a) the fair market value of the Optional Conversion Shares and (b) an amount equal to the product obtained by multiplying (A) the Stated Value by (B) 2.0. During 2013, the Company issued an aggregate of 20,000 shares of its Series J Preferred Stock at a price of $1,000 per share for aggregate proceeds of $20.0 million. The shares of Series J Preferred Stock were issued pursuant to a preferred stock subscription agreement among the Company, PCA Holdings, Holdings II and Riverwood. The Company issued 13,657; 2,500; 2,394 and 1,449 shares of Series J Preferred Stock to Holdings II, PCA Holdings, Riverwood Holdings and other accredited investors, respectively (the “Initial Series J Investors”). As compensation for advisory services provided by Pegasus, on September 11, 2013 the Company issued a warrant to Holdings II (the “Pegasus Warrant”), representing the right to purchase 10,000,000 shares of Common Stock at a variable exercise price that will be determined on the date of exercise of the Pegasus Warrant. During 2014, the Company issued an aggregate of 38,475 Series J Securities, at a purchase price of $1,000 per Series J Security for aggregate proceeds of $38.5 million. The Series J Securities were issued pursuant to separate subscription agreements between the Company and each of PCA Holdings, Holdings II, Riverwood Holdings, Cleantech A and Cleantech B, Serengeti Lycaon MM L.P., (“Serengeti Lycaon”), Serengeti Opportunities MM L.P, (“Serengeti Opportunities, and together with Serengeti Lycaon, “Serengeti”) and certain other accredited investors. The Company issued 13,000; 6,000; 14,000; 2,860; 2,570 and 45 Series J Securities to Serengeti, Holdings II, PCA Holdings, Riverwood Holdings, Zouk and other accredited investors, respectively. In addition, because one of the offerings of Series J Preferred Stock in 2014 was deemed to be a “qualified follow-on” under the certificate of designation governing the Series J Preferred Stock in effect at such time as well as the subscription agreements by and between the Company and the Initial Series J Investors, the Initial Series J Investors were entitled to exchange their shares of Series J Preferred Stock for Series J Securities. Accordingly, in January 2014, the Company issued 13,657; 2,500; 2,394 and 1,449 Series J Securities to LSGC Holdings II, PCA Holdings, Riverwood Holdings and the other Initial Series J Investors, respectively. During 2015, the Company issued an aggregate of 21,587 Series J Securities to Holdings III and certain existing preferred stockholders upon exercise of their preemptive rights under the certificates of designation governing the Convertible Preferred Stock. In each case, the Series J Securities were issued at a purchase price of $1,000 per Series J Security, and the Company received aggregate gross proceeds of approximately $21.6 million in connection with these issuances. As of December 31, 2015, the Company had issued an aggregate of 80,062 shares of Series J Preferred Stock and Series J Warrants to purchase an aggregate of 212,164,300 shares of Common Stock. In accordance with ASC 480, “Distinguishing Liabilities from Equity” (“AS 480”), the shares of Convertible Preferred Stock are recorded as mezzanine equity because the holders of such shares are allowed to redeem the shares for cash, and redemption is not solely within the control of the Company. In accordance with ASC 480-10-S99, the Company will recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the shares of Convertible Preferred Stock to equal the redemption value at the end of each reporting period. Shares of Convertible Preferred Stock were recorded at redemption value on each date of issuance, which included a deemed dividend due to the redemption feature. T he Series H Preferred Stock and Series I Preferred Stock were recorded at redemption value during the year ended December 31, 2012, with an aggregate deemed dividend of $203.6 million, which was reflected as an offset in additional paid in capital. There was no change in the redemption value of the Series H Preferred Stock and Series I Preferred Stock during the years ended December 31, 2015 and 2014. As of December 31, 2015, Series J Preferred Stock redemption value included an aggregate deemed dividend of $117.7 million, which is reflected as an offset in additional paid-in capital. In December 2015, the Company issued 20,106.03 Series K Securities to Pegasus Fund IV pursuant to the Subscription and Support Agreement. The number of Series K Securities issued to Pegasus Fund IV was determined based on the quotient obtained by dividing (x) the aggregate amount of the bonds, undertakings, guarantees and/or contractual obligations underlying Pegasus Fund IV’s initial commitment with respect to the Appeal Bond by (y) $1,000. The Series K Preferred Stock is senior to the Common Stock and Convertible Preferred Stock. Depending on whether the Appeal Bond has been drawn or fully released, the Series K Certificate of Designation requires the Company to redeem the outstanding shares of Series K Preferred Stock in the event of a liquidation, dissolution or winding up of the Company or an earlier change of control or “junior security redemption,” which includes events triggering a redemption of the outstanding shares of Convertible Preferred Stock. In accordance with ASC 480, the shares of Series K Preferred Stock are recorded as mezzanine equity because the holders of such shares are allowed to redeem the shares for cash. The Series K Preferred Stock was initially recorded at fair value (of $1.1 million) with a deemed dividend recorded in additional paid in capital. The deemed dividend was attributed to the shares held by the controlling stockholders. Subsequently, the Series K Preferred Stock was recorded at redemption value which included a deemed dividend as a result of its redemption feature. As a result, the Company recorded a $19.0 million deemed dividend due to the accretion of the Series K Preferred Stock to its redemption value.

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 11: Stockholders’ Equity Common Stock Issuances On March 24, 2015, the Company issued 2,033,905 shares of restricted stock in settlement of director fees for the year ended December 31, 201 5. The shares of restricted stock were scheduled to vest on January 1, 2016, provided that the applicable director was still in office at such time. On November 19, 2015, the Company cancelled 1,459,521 of such shares of restricted stock and, as consideration for the cancelled shares, issued stock options representing the right to purchase an aggregate of 3,132,020 shares of Common Stock to certain directors. The options vested in full on January 1, 2016. On March 25, 2014, the Company issued 1,484,931 shares of restricted stock in settlement of director fees for the year ended December 31, 2014. In connection with new director appointments and changes in committee composition, the Company issued 150,137, 110,685 and 78,360 shares of restricted stock on April 1, 2014, June 12, 2014 and August 28, 2014, respectively, in settlement of the pro rata portion of director fees for the relevant director’s period of service during 2014. The shares of restricted stock vested on January 1, 2015, provided that the director was still in office at such time. On June 12, 2014, the Board approved the formation of a Scientific Advisory Board (the “SAB”) and issued restricted stock awards to each of the five members of the SAB as part of their compensation package. For the years ended December 31, 2015 and 2014, the Company recorded expense of $37,000 and $64,000, respectively, related to restricted stock awards to the Company’s SAB. For the years ended December 31, 2015, 2014 and 2013, the Company recorded expenses of $79,000 , $670,000 and $725,000, respectively, related to the restricted stock awards and$280,000 , $0 and $21,000, Warrants for the Purchase of Common Stock THD Warrant. As a result of the issuances of certain securities during 2012, 2013, 2014 and 2015, the exercise price and the number of shares into which the THD Warrant is exercisable were adjusted in accordance with the terms of the THD Warrant. Further, the tranches of shares underlying the THD Warrant that vested on December 31, 2011 and December 31, 2012 have expired. As of December 31, 2015, the THD Warrant represented the right to purchase 6,342,324 shares of Common Stock at an exercise price of $0.95 per share. Series D Warrants. issued in connection with the Company’s Series D Non-Convertible Preferred Stock (the “Series D Warrants”) also have certain adjustment features. As a result of the issuances of certain securities during 2012, 2013, 2014 and 2015, the exercise price and the number of shares into which the Series D Warrants are exercisable were adjusted in accordance with the terms of the Series D Warrants. Further, in 2012, certain holders exchanged their Series D Warrants for shares of Common Stock. As of December 31, 2015, the Series D Warrants had exercise prices ranging from $2.65 to $2.67 and were exercisable into an aggregate of 1,192,048 shares of Common Stock Riverwood Warrants. September 2012 Warrants. September 2012 Commitment Agreement Pegasus Warrant Series J Warrants. Series K Warrant Other Outstanding Warrants As of December 31, 2015, the Company had outstanding the following warrants for the purchase of Common Stock: Warrant Holder Reason for Issuance Number of Underlying Shares Exercise Price Expiration Date Investors in rights offering Series D Warrants 1,192,048 $2.65 to $2.66 March 3, 2022 through April 19, 2022 The Home Depot Purchasing agreement 6,342,324 $ 0.95 December 31, 2016 through 2018 RW LSG Management Holdings LLC Riverwood Warrants 12,664,760 Variable May 25, 2022 Certain other investors Riverwood Warrants 5,427,751 Variable May 25, 2022 Cleantech Europe II (A) LP September 2012 Warrants 3,406,041 $ 0.72 September 25, 2022 Cleantech Europe II (B) LP September 2012 Warrants 593,959 $ 0.72 September 25, 2022 Portman Limited September 2012 Warrants 4,000,000 $ 0.72 September 25, 2022 Aquillian Investments LLC Private Placement Series H 830,508 $ 1.18 September 25, 2017 Pegasus Pegasus Warrant 10,000,000 Variable May 25, 2022 Series J Holders Series J Warrants 212,164,300 $ 0.001 January 3, 2019 through January 30, 2020 Medley Medley Warrants 10,000,000 $ 0.95 February 19, 2024 Pegasus Pegasus Guaranty Warrants 10,000,000 $ 0.50 February 19, 2024 Pegasus Series K Warrants 14,777,932 $ 0.12 December 31, 2025 291,399,623 As of December 31, 2015, the Series D Warrants, the warrants held by Aquillian Investments LLC, the September 2012 Warrants, the Series J Warrants, the Medley Warrants , the Pegasus Guaranty Warrants and a portion of the THD Warrants were fully vested and exercisable. In accordance with the vesting terms discussed above, no shares issuable pursuant to the THD Warrant vested for the years ended December 31, 2015 and 2013 and 2,114,108 shares issuable pursuant to the THD Warrant vested during the years ended December 31, 2014. Accordingly, as of December 31, 2015, THD Warrant represented a right to purchase 6,342,324 shares of common stock and 2,114,108 underlying shares remain subject to vesting upon satisfaction of prescribed product purchasing terms. As of December 31, 2015, a tranche of the THD Warrant that vested in 2012, representing the right to purchase 2,114,107 shares, expired. The Series K Warrants are not exercisable until after the Appeal Bond has been fully drawn or all commitments thereunder have been released. Pursuant to the terms of the Riverwood Warrants and the Pegasus Warrant, such warrants were not exercisable as of December 31, 2015 because the aggregate fair market value of the Company’s outstanding shares of Common Stock (as determined in accordance with the terms of the Riverwood Warrants and the Pegasus Warrant) was less than $580.0 million (subject to adjustment in accordance with the terms of the Riverwood Warrants and the Pegasus Warrant) . The fair value of the THD Warrant is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until they have been earned for each year and these adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot. For the years ended December 31, 2015, 2014 and 2013, the Company recorded $64,000, $103,000 and $0 as a reduction in revenue, respectively. The change in fair value of the previously vested portion of the THD Warrant was an increase of $83,000 for the year ended December 31, 2015, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss.

Note 12 - Earnings (Loss) Per S

Note 12 - Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 1 2 : Earnings (Loss) Per Share In 2012, the Company determined that two classes of Common Stock had been established for financial reporting purposes only, with Common Stock attributable to controlling stockholders representing shares beneficially owned and controlled by Pegasus Capital and its affiliates and the Common Stock attributable to noncontrolling stockholders representing the minority interest stockholders. For the years ended December 31, 2015, 2014 and 2013, the Company computed net loss per share of noncontrolling stockholders and controlling stockholders Common Stock using the two-class method. Net loss from operations is initially allocated based on the underlying common shares held by controlling and noncontrolling stockholders. The allocation of the net losses attributable to the Common Stock attributable to controlling stockholders is then reduced by the amount of the deemed dividends . The following table sets forth the computation of basic and diluted net loss per share of Common Stock: For the Years Ended December 31, 2015 2014 2013 Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Basic and diluted net income per share: Net loss from operations $ (20,449,368 ) $ (6,638,142 ) $ (52,134,928 ) $ (13,459,745 ) $ (74,506,560 ) $ (15,310,772 ) Deemed dividends related to the Series H, I and J Preferred Stock attributable to all shareholders (23,263,854 ) (7,551,762 ) (49,687,773 ) (12,827,960 ) (20,206,288 ) (4,152,304 ) Deemed dividends due to the issuance of Series K Preferred Stock as compensation for bond provided by controlling shareholders 1,147,766 (1,147,766 ) - - - - Deemed dividends due to the accretion of Series K Preferred Stock (14,312,298 ) (4,645,966 ) Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders - - 570,574 (570,574 ) - - Undistributed net loss $ (56,877,755 ) $ (19,983,635 ) $ (101,252,127 ) $ (26,858,279 ) $ (94,712,848 ) $ (19,463,076 ) Basic and diluted weighted average number of common shares outstanding 303,742,731 98,598,998 232,409,186 60,001,396 170,662,220 35,070,340 Basic and diluted net loss per common share: $ (0.19 ) $ (0.20 ) $ (0.44 ) $ (0.45 ) $ (0.55 ) $ (0.55 ) Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the applicable period. The Series J Warrants have an exercise price of $0.001 per share of Common Stock, and are included in the weighted average number of shares of Common Stock outstanding as there are no conditions that must be satisfied before such warrant may be exercised into the shares of Common Stock underlying such warrants. Diluted earnings per share is computed in the same manner as basic earnings per share except the number of shares is increased to assume exercise of potentially dilutive stock options, unvested restricted stock and contingently issuable shares using the treasury stock method and convertible preferred shares using the if-converted method, unless the effect of such increases would be anti-dilutive. The Company had 265.8 million, 180.5 million and 88.1 million common stock equivalents for the years ended December 31, 2015, 2014 and 2013, respectively, which were not included in the diluted net loss per common share as the common stock equivalents were anti-dilutive, as a result of being in a net loss position.

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 13: Related Party Transactions On February 19, 2014, the Company entered into the Pegasus Guaranty and, as consideration for the Pegasus Guaranty, the Company issued the Pegasus Guaranty Warrants to the Pegasus Guarantors. The Pegasus Guaranty Warrants were valued at $3.3 million as of February 19, 2014, which was partially offset by the $2.8 million fair value of the Pegasus Guaranty, with the remaining value of $571,000 accounted for as a deemed dividend to the Company’s controlling stockholders. For the years ended December 31, 2015 and 2014, the Company recorded $553,000 and $476,000, respectively, of non-cash related party interest expense related to the amortization of the Pegasus Guaranty. During the years ended December 31, 2015, 2014 and 2013, the Company incurred consulting fees of $3,000, $12, 000 and $14,000, respectively, for services provided by T&M Protection Resources which were included in selling, distribution and administrative expense. T&M Protection Resources is a security company affiliated with Pegasus Capital. On September 11, 2015 and January 30, 2015, the Company issued 10,000 and 11,525 Series J Securities, respectively, to Holdings III, in each case at a purchase price of $1,000 per Series J Security for aggregate gross proceeds of $21.5 million. The Series J Securities were issued pursuant to subscription agreements between the Company and Holdings III, an affiliate of Pegasus Capital. On December 7, 2015, in consideration of Pegasus Fund IV’s entry into the Appeal Bond Agreements and as security for the potential payments to be made to the issuer of the Appeal Bond for draws upon the Appeal Bond, the Company issued 20,106.03 Series K Securities to Pegasus Fund IV pursuant to the Subscription and Support Agreement. The number of Series K Securities issued to Pegasus Fund IV was determined based on the quotient obtained by dividing (x) the aggregate amount of the bonds, undertakings, guarantees and/or contractual obligations underlying Pegasus Fund IV’s initial commitment with respect to the Appeal Bond by (y) $1,000. On January 3, 2014, the Company issued 2,860 Series J Securities to Riverwood Holdings for aggregate proceeds of $2.9 million. On January 9, 2014, the Company issued 2,570 Series J Securities to Zouk for aggregate proceeds of $2.6 million. On January 3, 2014, the Company issued 2,000 and 6,000 Series J Securities to PCA Holdings and Holdings II, respectively, for aggregate proceeds of $8.0 million. On January 9, 2014, the Company issued 4,000 Series J Securities to PCA Holdings for aggregate proceeds of $4.0 million. From August 14 through August 28, 2014, the Company issued an aggregate of 8,000 Series J Securities to PCA Holdings for aggregate proceeds of $8.0 million.

Note 14 - Equity Based Compensa

Note 14 - Equity Based Compensation Plans	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 14: Equity Based Compensation Plans The Company currently has one equity-based compensation plan, the 2012 Amended and Restated Equity-Based Compensation Plan, (the “Equity Plan”). Awards granted under the Equity Plan may include incentive stock options, which are qualified under Section 422 of the Internal Revenue Code (the “Code”), stock options other than incentive stock options, which are not qualified under Section 422 of the Code, stock appreciation rights, restricted stock, phantom stock, bonus stock and awards in lieu of obligations, dividend equivalents and other stock-based awards. On September 9, 2014, holders of a majority of the Company’s Common Stock executed a written consent in lieu of a special meeting approving an amendment to the Equity Plan that (i) increased the total number of shares of Common Stock available for issuance thereunder from 55.0 million to 155.0 million and (ii) increased the maximum number of stock options or stock appreciation rights that may be granted each fiscal year to any Covered Employee (as defined in the Equity Plan) from 7.0 million to 30.0 million. As of December 31, 2015, there were 90.1 million shares remaining for future grants. Awards may be granted to employees, members of the Board of Directors, and consultants. The Equity Plan is generally administered by the Compensation Committee of the Board of Directors. Vesting periods and terms for awards are determined by the plan administrator. The exercise price of each stock option or stock appreciation right is equal to or greater than the market price of the Company’s stock on the date of grant and no stock option or stock appreciation right granted may have a term in excess of ten years. The Board of Directors may also issue stock-based awards to the Company’s nonemployee directors who wish their awards to be issued to an entity other than an individual under the Directors Stock Plan (the “Directors Plan”). As of December 31, 2015, the Company has reserved an aggregate of 5 million shares of Common Stock for issuance under the Directors Plan. The total number of shares outstanding under the Directors Plan was 1,150,456 shares as of December 31, 2015. Stock Option Awards The following table summarizes stock option activity for all of the Company’s stock-based plans as of December 31, 2015 and changes during the year then ended: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2014 44,281,364 $ 0.56 Granted 24,416,277 0.14 Exercised - - Forfeited or expired (8,570,994 ) 1.07 Outstanding as of December 31, 2015 60,126,647 $ 0.31 8.35 $ - Vested or expected to vest as of December 31, 2015 48,712,673 $ 0.35 8.16 $ - Exercisable as of December 31, 2015 17,577,168 $ 0.64 6.46 $ - The total intrinsic value in the table above represents the total pretax intrinsic value, which is the total difference between the closing price of the Company’s Common Stock on December 31, 2015 and the exercise price for each in-the-money option that would have been received by the holders if all instruments had been exercised on December 31, 2015. This value fluctuates with the changes in the price of the Company’s Common Stock. As of December 31, 2015, there was $3.6 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of 3.38 years. The following table summarizes information about stock options outstanding and exercisable as of December 31, 2015: Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Average Remaining Contractual Term Weighted Average Exercise Price Number Weighted Average Exercise Price $0.11 - $0.11 14,024,257 9.80 $ 0.11 2,326,445 $ 0.11 $0.13 - $0.13 3,132,020 9.88 0.13 - - $0.18 - $0.18 27,800,000 8.77 0.18 6,950,000 0.18 $0.20 - $1.00 12,091,998 6.42 0.55 5,714,248 0.89 $1.04 - $4.35 3,069,122 4.01 1.70 2,577,225 1.77 $7.40 - $7.40 3,000 1.11 7.40 3,000 7.40 $10.80 - $10.80 6,250 1.59 10.80 6,250 10.80 Total 60,126,647 8.35 $ 0.31 17,577,168 $ 0.64 Other information pertaining to stock options is as follows: For the Years Ended December 31, 2015 2014 2013 Weighted average grant date fair value per share of options $ 0.11 $ 0.14 $ 0.39 Total intrinsic value of options exercised $ - $ - $ - Restricted Stock Awards A summary of unvested shares of restricted stock outstanding under all of the Company’s stock-based plans as of December 31, 2015 and changes during the year then ended is as follows: Number of Shares Weighted Average Grant Date Fair Value Unnvested as of December 31, 2014 2,080,342 $ 0.38 Granted 2,033,905 0.20 Vested (2,221,177 ) 0.36 Forfeited (1,693,070 ) 0.21 Unvested as of December 31, 2015 200,000 $ 0.20 As of December 31, 2015, there was no unrecognized compensation cost related to restricted stock granted under the Equity Plan or the Directors Plan. For the years ended December 31, 2015, 2014 and 2013, the Company recorded compensation expense related to restricted stock of $121,000, $730 ,000 and $891,000, respectively. Stock–Based Compensation Valuation and Expense The Company accounts for its stock-based compensation plans using the fair value method. The fair value method requires the Company to estimate the grant date fair value of its stock based awards and amortize this fair value to compensation expense over the requisite service period or vesting term. To estimate the fair value of the Company’s stock-based awards the Company currently uses the Black-Scholes pricing model. The determination of the fair value of stock-based awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends. Due to the inherent limitations of option-valuation models available today, including future events that are unpredictable and the estimation process utilized in determining the valuation of the stock-based awards, the ultimate value realized by award holders may vary significantly from the amounts expensed in the Company’s financial statements. For restricted stock awards, grant date fair value is based upon the market price of the Company’s Common Stock on the date of the grant. This fair value is then amortized to compensation expense over the requisite service period or vesting term. Stock-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those stock-based awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. The Company recorded stock option expense of $2.1 million, $3.3 million and $6.9 million for the years ended December 31, 2015, 2014 and 2013, respectively. The weighted average assumptions used to value stock option grants were as follows: For the Years Ended December 31, Variable Ranges 2015 2014 2013 Exercise price $0.11 - $0.24 $0.18 - $0.50 $0.44 - $0.70 Fair market value of the underlying stock on date of grant $0.11 - $0.24 $0.18 - $0.42 $0.38 - $0.64 Stock Option Grants: Risk-free interest rate 1.31% - 1.68% 0.209% - 2.07% 1.03% - 2.00% Expected life, in years 5.06 - 6.25 1.75 - 6.25 6.00 - 6.25 Expected volatility 91.86% - 102.48% 67.32% - 100.46% 99.51% - 101.82% Expected dividend yield 0.0% 0.0% 0.0% Expected forfeiture rate 14.93% 19.19% 7.49% Fair value per share $0.12 - $0.28 $0.12 - $0.28 $0.08 - $0.52 The following describes each of these assumptions and the Company’s methodology for determining each assumption: Risk-Free Interest Rate The Company estimates the risk-free interest rate using the U.S. Treasury bill rate with a remaining term equal to the expected life of the award. Expected Life The expected life represents the period that the stock option awards are expected to be outstanding derived using the “simplified” method as allowed under the provisions of the SEC’s Staff Accounting Bulletin No. 107 as the Company does not believe it has sufficient historical data to support a more detailed assessment of the estimate. Expected Volatility The Company estimates expected volatility based on the historical volatility of the Company’s Common Stock and its peers. Expected Dividend Yield The Company estimates the expected dividend yield by giving consideration to its current dividend policies as well as those anticipated in the future considering the Company’s current plans and projections. 2011 Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan (the “2011 ESPP”) that provides employees with the opportunity to purchase Common Stock at a discount. All employees of the Company and any designated subsidiary are eligible to participate in the 2011 ESPP, subject to certain exceptions. As of December 31, 2015, there were 2.0 million shares authorized for issuance under the ESPP, with 1.8 million shares remaining for future issuance. The 2011 ESPP is a qualified employee stock purchase plan under Section 423 of the Code and was approved by the Company’s stockholders at its annual meeting on August 10, 2011. The purpose of the 2011 ESPP is to provide employees of the Company and designated subsidiaries with an opportunity to acquire a proprietary interest in the Company. Accordingly, the 2011 ESPP offers eligible employees the opportunity to purchase shares of Common Stock of the Company at a discount to the market value through voluntary systematic payroll deductions. For the 2015 offering under the 2011 ESPP, a participant could elect to use up to 30% of his or her compensation to purchase whole shares of Common Stock of the Company, but could not purchase more than 2,000 shares during the year. The purchase price for each purchase period is 85% of the fair market value of a share of Common Stock of the Company on the purchase date, rounded up to the nearest whole cent. Unless sooner terminated by the board of directors, the 2011 ESPP will remain in effect until December 31, 2020. During the years ended December 31, 2015, 2014 and 2013, the Company issued 9,975, 23,126 and 88,284 shares to certain employees under the 2011 ESPP at prices ranging from $0.13 to $2.32 per share.

Note 15 - Restructuring Expense

Note 15 - Restructuring Expense	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	Note 15: Restructuring Expenses The following table summarizes our restructuring expenses and related charges for the following years ended December 31: For the Years Ended December 31, 2015 2014 2013 Broad based reduction of facilities and personnel (1) $ 1,883,326 $ 3,314,251 $ 4,479,076 Mexico Closing (2) - - 102,688 Organization Optimization Initiative (3) - 114,277 77,061 Total $ 1,883,326 $ 3,428,528 $ 4,658,825 (1) These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reduction in Satellite Beach, Florida of approximately 69 positions, including the termination of several members of the Company’s senior management and a $3.2 million write-down of property and equipment, cost reductions in our foreign subsidiaries and refocusing the Company’s efforts within North America, which resulted in the elimination of all employees at LSGBV and LSIPL. (2) On September 24, 2012, the Company’s Board of Directors committed to the closing of our manufacturing facility in Mexico (the “Mexico Closing”), which was substantially complete as of December 31, 2013. The Mexico Closing resulted in the termination of approximately 520 employees and $1.7 million in a non-cash asset impairment. (3) In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company’s continued shift of its manufacturing and production processes to the Company’s contract manufacturer in Mexico, the replacement of ten members of management in the United States and the closing of the Company’s offices in the United Kingdom and Australia. As of December 31, 2014, this plan was complete. As of December 31, 2015 and 2014, the accrued liability associated with the restructuring and other related charges consisted of the following: Workforce Excess Other Reduction Facilities Exit Costs Total Accrued liability as of December 31, 2013 $ 699,832 $ - $ 276,956 $ 976,788 Charges 2,496,184 311,269 122,054 2,929,507 Payments (2,236,776 ) - (218,170 ) (2,454,946 ) Accrued liability as of December 31, 2014 $ 959,240 $ 311,269 $ 180,840 $ 1,451,349 Charges 297,770 - - 297,770 Payments (1,117,625 ) (69,776 ) (167,960 ) (1,355,361 ) Accrued liability as of December 31, 2015 $ 139,385 $ 241,493 $ 12,880 $ 393,758 The remaining accrual of $394,000 as of December 31, 2015 is expected to be paid during the year ending December 31, 2016. The restructuring and other related charges are included in the line item restructuring expenses in the consolidated statements of operations.

Note 16 - Income Taxes

Note 16 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 16: Income Taxes The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes” (“ASC 740”). Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The components of the consolidated income tax benefit from continuing operations are as follows: For the Years Ended December 31, 2015 2014 2013 Loss before taxes Domestic $ (26,652,135 ) $ (64,343,390 ) $ (86,599,121 ) Foreign (418,873 ) (1,251,283 ) (3,218,211 ) Total $ (27,071,008 ) $ (65,594,673 ) $ (89,817,332 ) The reconciliation of the provision for income taxes from continuing operations at the United States Federal statutory tax rate of 34% is as follows: For the Years Ended December 31, 2015 2014 2013 Loss before taxes $ (27,071,008 ) $ (65,594,673 ) $ (89,817,332 ) Income tax benefit applying United States federal statutory rate of 34% (9,204,143 ) $ (22,302,189 ) $ (30,537,893 ) State taxes, net of federal benefit (776,264 ) (1,183,397 ) (1,674,412 ) Permanent differences Derivative fair value adjustment 203,498 5,359,878 (1,323,618 ) Other 26,037 - 40,669 Increase in valuation allowance 4,763,028 30,513,501 31,336,114 Change in effective tax rate - United States (2,910,847 ) (2,679,697 ) 1,597,640 Change in effective tax rate - foreign - - - Expiration/true-up of NOL's 7,840,050 (10,236,058 ) 110,950 Rate difference between United States federal statutory rate and Netherlands statutory rate 58,642 175,180 450,550 Other - 352,782 - Income tax expense (benefit) $ - $ - $ - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred income taxes are as follows: As of December 31, 2015 2014 Deferred income tax assets Net operating loss carryforwards $ 188,129,680 $ 181,983,692 Stock based compensation 9,825,558 8,957,780 Inventories 2,569,531 2,864,989 Warranty liability 1,235,724 1,745,093 Fixed asset impairment 616,709 1,168,224 Accrued legal fees 945,664 552,889 Goodwill impairment on asset acquisition 459,591 871,229 Accrued rebates 843,340 448,481 Accounts receivable 165,495 138,221 Accrued compensation 154,130 357,750 Charitable contribution carryforward 67,682 56,979 Depreciation 66,987 66,775 Accrued Expenses 55,691 - India start-up costs 33,136 32,645 Reserve for losses on non-cancelable purchase commitments - 172,110 Accrued Florida use tax - 830 Total deferred income tax assets 205,168,916 199,417,687 Less: valuation allowance (203,452,854 ) (198,689,826 ) Net deferred tax assets $ 1,716,063 $ 727,861 Deferred income tax liabilities Stock losses $ (171,976 ) $ (169,409 ) Interest Expense (14,004 ) Loss on disposal of long-lived assets (1,530,083 ) (558,452 ) Total deferred income tax liabilities (1,716,063 ) (727,861 ) Net deferred tax liabilities $ - $ - ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all evidence, both positive and negative, management has determined that a $203.5 million valuation allowance as of December 31, 2015 is necessary to reduce the deferred tax assets to the amount that will more likely than not be realized. The change in the valuation allowance for the current year is $4.8 million. As of December 31, 2015, the Company had tax loss carryforwards available to offset future income taxes, subject to expiration as follows: Year of Expiration United States Net Operating Tax Loss Carryforwards The Netherlands Net Operating Tax Loss Carryforwards 2016 - 3,869,995 2017 - 4,265,206 2018 5,357,429 4,692,440 2019 2,293,432 908,706 2020 1,473,066 908,568 2021 2,769,043 2,027,511 2022 1,840,300 - 2023 2,031,270 - 2024 3,353,481 - 2025 2,293,432 - 2026 2,293,432 - 2027 9,937,230 - 2028 29,631,134 - 2029 33,916,312 - 2030 50,887,617 2031 67,057,312 2032 90,683,320 2033 82,316,468 2034 59,822,398 2035 28,057,263 Total $ 476,013,939 $ 16,672,426 At the time of the reverse merger transaction and resulting change in control, in June 2007, the Company had accumulated approximately $75.0 million in loss carryforwards. As a result of the change in control, the Company is limited by Section 382 of the Internal Revenue Code in the amount of loss carryforwards that it may apply to its taxable income in any tax year. These loss carryforwards expire from 2018 through 2035. To the extent the Company is able to utilize available loss carryforwards that arose from operations in tax years prior to September 26, 2003, any benefit realized will be credited to income tax expense. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2015 and 2014, the Company had no unrecognized tax benefits. The Company’s policy is to recognize interest and penalties related to income taxes in its income tax provision. The Company has not accrued or paid interest or penalties which were material to its results of operations for the years ended December 31, 2015, 2014 and 2013. The Company files income tax returns in its U.S. federal jurisdictions and various state jurisdictions. As of December 31, 2015, the Company’s income tax returns prior to 2011 and 2010 are closed to examination for federal and state purposes, respectively. The Company’s 2013 federal income tax return is currently being examined by the Internal Revenue Service. The Company does not anticipate any material change in the next 12 months for uncertain tax positions.

Note 17 - Concentrations of Cre

Note 17 - Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 17: Concentrations of Credit Risk For the years ended December 31, 2015, 2014 and 2013, the Company had one customer whose revenue represented 91% and 80% and 55% of total revenue, respectively. The loss of this material relationship would have a material adverse effect on our results of operations and cash flows . As of December 31, 2015 and 2014, the Company had one customer whose accounts receivable balance represented 70% and 66% of accounts receivables, net of allowances, respectively.

Note 18 - Commitments and Conti

Note 18 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 18: Commitments and Contingencies Purchase Commitments As of December 31, 2015, the Company had $9.2 million in purchase commitments, which are generally non-cancellable. Lease Commitments As of December 31, 2015, the Company had the following commitments under operating leases for property and equipment for each of the next five years: Year Amount 2016 $ 398,461 2017 317,777 2018 276,705 2019 276,705 2020 - Thereafter - $ 1,269,648 During the years ended December 31, 2015, 2014 and 2013, the Company incurred rent expense of $459,000, $1.7 million and $2.1 million, respectively. Agreements with Contract Manufacturers The Company currently depends on a small number of contract manufacturers to manufacture its products. If any of these contract manufacturers were to terminate their agreements with the Company or fail to provide the required capacity and quality on a timely basis, the Company may be unable to manufacture and ship products until replacement contract manufacturing services could be obtained. Other Contingencies The Company is subject to the possibility of loss contingencies arising in its business and such contingencies are accounted for in accordance with ASC Topic 450, "Contingencies.” In determining loss contingencies, the Company considers the possibility of a loss as well as the ability to reasonably estimate the amount of such loss or liability. An estimated loss is recorded when it is considered probable that a liability has been incurred and when the amount of loss can be reasonably estimated. In the ordinary course of business, the Company is routinely a defendant in or party to various pending and threatened legal claims and proceedings. The Company believes that any liability resulting from these various claims will not have a material adverse effect on its results of operations or financial condition; however, it is possible that extraordinary or unexpected legal fees could adversely impact our financial results during a particular period. During its ordinary course of business, the Company enters into obligations to defend, indemnify and/or hold harmless various customers, officers, directors, employees, and other third parties. These contractual obligations could give rise to additional litigation costs and involvement in court proceedings. On June 22, 2012, Geveran filed a lawsuit against the Company and several others in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. On October 30, 2012, the court entered an order transferring the lawsuit to the Ninth Judicial Circuit in and for Orange County, Florida. The action, styled Geveran Investments Limited v. Lighting Science Group Corp., et al., Case No. 12-17738 (07), names the Company as a defendant, as well as Pegasus Capital and nine other entities affiliated with Pegasus Capital; Richard Weinberg, our former Director and former interim Chief Executive Officer and a former partner of Pegasus Capital; Gregory Kaiser, a former Chief Financial Officer; J.P. Morgan Securities, LLC (“J.P. Morgan”); and two employees of J.P. Morgan. Geveran seeks rescission of its $25.0 million investment in the Company, as well as recovery of interest, attorneys’ fees and court costs, jointly and severally against the Company, Pegasus Capital, Mr. Weinberg, Mr. Kaiser, J.P. Morgan and the two J.P. Morgan employees, for alleged violations of Florida securities laws. Geveran alternatively seeks unspecified money damages, as well as recovery of court costs, for alleged common law negligent misrepresentation against these same defendants. On August 28, 2014, the court issued an Order Granting Plaintiff’s Motion for Partial Summary Judgment under its First Cause of Action for Violation of the Florida Securities and Investor Protection Act. On November 25, 2015, entered judgment against the defendants, including the Company, on a joint and several basis, in the amount of approximately $40.2 million. On December 4, 2015, the Company, along with the other defendants, filed a Notice of Appeal to the Florida Fifth District Court of Appeal and posted a bond securing the judgment in the amount of approximately $20.1 million. Defendant J.P. Morgan also posted a separate bond in the amount of approximately $20.1 million, resulting in total bonding of approximately $40.2 million. On March 29, 2016, the trial court judge determined that the posted bonds were sufficient security to stay execution of the judgment pending the appeal. Although we cannot predict the ultimate outcome of this lawsuit, we believe the court’s summary judgment award in favor of Geveran was in error, that we will prevail on the appeal and the judgment will be overturned, and that the case will be remanded to the trial court for further proceedings. Were that to occur, we believe we have strong defenses against Geveran’s claims. However, in the event that we are not successful on appeal, we could be liable for the full amount of the $40.2 million judgment, plus post judgment interest. Such an outcome would have a material adverse effect on our financial position. The Company believes that, subject to the terms and conditions of the relevant policies (including retention and policy limits), directors’ and officers’ insurance coverage will be available to cover the substantial majority of its legal fees and costs in this matter. However, insurance coverage may not be available for, or such coverage may not be sufficient to fully pay, a judgment or settlement in favor of Geveran. Based upon the terms of an indemnification agreement, the Company has also paid, and may be required to pay in the in the future, reasonable legal expenses incurred by J.P. Morgan and its affiliates in this lawsuit in connection with the engagement of J.P. Morgan as placement agent for the private placement with Geveran. Such payments are not covered by the Company’s insurance coverage. The engagement letter executed with J.P. Morgan provides that the Company will indemnify J.P. Morgan and its affiliates from liabilities relating to J.P. Morgan’s activities as placement agent, unless such activities are finally judicially determined to have resulted from J.P. Morgan’s bad faith, gross negligence or willful misconduct. The Company is also a defendant in action brought by GE Lighting Solutions LLC (“GE Lighting”) in Federal District Court for the Northern District of Ohio in or about January 2013. GE Lighting asserts a claim of patent infringement against the Company under U.S Patent No. 6,787,999, entitled LED-Based Modular , and U.S . Patent No. 6,799,864, entitled High Power LED Power Pack for Spot Module Illumination . If GE Lighting were to prevail on its appeal, the case would likely be remanded to the trial court for further proceedings. Were that to occur, we believe that we have strong defenses against GE Lighting’s claims. However, if GE Lighting’s appeal is successful, there is no assurance that we will be successful in defending against this action. The outcome, if unfavorable, could have a material adverse effect on our financial position. Even if the outcome is favorable, this litigation could result in substantial additional costs to us, could be a distraction to management and could harm our financial position. In April 2015, LSG filed a lawsuit against several former employees and a company they formed seeking damages and injunctive relief arising out of the defendants’ misappropriation of our trade secrets and other intellectual property. Pursuant to the terms of a settlement agreement entered into in December 2015, certain of the individual defendants agreed not to use or disclose our intellectual property and to reimburse us for $200,000 in costs, and the defendants’ company agreed to pay us a commission equal to the greater of (i) $1.7 million and (ii) 5% of such company’s gross sales of biological and agricultural products during the three-year period ending January 2019 . In addition, the Company may be a party to a variety of legal actions, such as employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims, shareholder suits, including securities fraud, intellectual property related litigation, and a variety of legal actions relating to its business operations. In some cases, substantial punitive damages may be sought. The Company currently has insurance coverage for certain of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be sufficient to cover the damages awarded. In addition, certain types of damages, such as punitive damages, may not be covered by insurance and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future.

Note 19 - Defined Contribution

Note 19 - Defined Contribution Plan	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 19: Defined Contribution Plan The Company has a qualified 401(k) plan (the “401(k) Plan”) covering substantially all employees in the United States. The 401(k) Plan was established under Internal Revenue Code Section 401(k). As of January 1, 2011, the Company began matching 50% of the first 6% of employee contributions and for the years ended December 31, 2015, 2014 and 2013, the Company contributed $135,000, $220,000 and $303,000, respectively, to the 401(k) Plan.

Note 20 - Quarterly Financial D

Note 20 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Quarterly Financial Information [Text Block]	Note 20: Quarterly Financial Data (Unaudited) The following is a summary of the Company’s consolidated quarterly results of operations for each of the years ended December 31, 2015 and 2014: 2015 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Revenue $ 19,371,545 $ 23,270,363 $ 19,587,399 $ 17,520,465 Gross margin 2,930,248 3,416,535 5,223,665 (369,184 ) Net income (loss) (13,601,090 ) (2,444,313 ) 269,344 (11,311,451 ) Basic and diluted net loss per weighted average common share attributable to controlling shareholders $ (0.07 ) $ (0.01 ) $ (0.04 ) $ (0.03 ) Basic and diluted net loss per weighted average common share attributable to noncontrolling shareholders $ (0.07 ) $ (0.01 ) $ (0.04 ) $ (0.03 ) 2014 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Revenue $ 25,925,841 $ 19,827,864 $ 23,089,356 $ 22,441,799 Gross margin 2,690,495 1,119,562 3,420,353 (3,648,278 ) Net loss (40,093,963 ) (11,628,516 ) (2,102,576 ) (11,769,618 ) Basic and diluted net loss per weighted average common share attributable to controlling shareholders $ (0.33 ) $ (0.04 ) $ (0.04 ) $ (0.09 ) Basic and diluted net loss per weighted average common share attributable to noncontrolling shareholders $ (0.35 ) $ (0.04 ) $ (0.04 ) $ (0.09 )

Note 21 - Valuation and Qualify

Note 21 - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Note 21: Valuation and Qualifying Accounts Valuation and qualifying accounts deducted from the assets to which they apply Balance as of Beginning of Period Currency Translation Adjustments Additions Charged to Costs and Expenses Additions Charged (Credited) to Other Accounts Deductions from Allowances Balance as of End of Period Allowance for doubtful accounts 2015 $ 408,047 (1,097 ) 83,105 - (15,031 ) $ 475,024 2014 $ 509,561 (8,574 ) 103,792 - (196,732 ) $ 408,047 2013 $ 1,188,366 7,381 279,757 - (965,943 ) $ 509,561 Provision for purchase commitments 2015 $ 540,227 (1,260 ) 115,926 (643,648 ) (11,245 ) $ - 2014 $ 1,629,806 (13,556 ) 507,257 (1,217,878 ) (365,402 ) $ 540,227 2013 $ 5,678,992 - 1,283,444 (4,562,550 ) (770,080 ) $ 1,629,806

Note 22 - Subsequent Events

Note 22 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	Note 22: Subsequent Events On February 23, 2016, the Company issued 3,000 Series J Securities to Holdings III pursuant to the Subscription and Support Agreement among the Company, Pegasus Fund IV and Holdings III for aggregate gross proceeds of $3.0 million.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenue and expenses. Such estimates include the valuation of accounts receivable, inventories, intangible assets and other long-lived assets, legal contingencies, and customer incentives, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an on -going basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency and energy markets and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency for the foreign operations of the Company is the local currency of the applicable foreign subsidiary. For the operations of Lighting Science Coöperatief U.A. and Lighting Science Group B.V. (“LSGBV”), the Company’s Netherlands-based subsidiaries, the functional currency is the Euro; for the operations of Lighting Science Group Mexico SRL, (“LSG Mexico”), the Company’s Mexican subsidiary, the functional currency is the Mexican Peso; for the operations of Lighting Science India Private Limited (“LSIPL”), the Company’s Indian subsidiary, the functional currency is the Indian Rupee; for the operations of Lighting Science Group HK Limited (“LSGHK”), the Company’s Hong Kong subsidiary, the functional currency is the Hong Kong Dollar; and for the operations of Lighting Science Group Shenzhen Co., Ltd (“LSGSZ”), the Company’s Chinese subsidiary, the functional currency is the Chinese Yuan Renminbi. The translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and for revenue and expense accounts using the average exchange rate for each period during the year. Any gains or losses resulting from the translation are included in accumulated other comprehensive loss in the consolidated statements of stockholders’ deficit and are excluded from net loss.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. As of both December 31, 2015 and 2014, the Company had no cash equivalents. The Company regularly maintains cash balances in excess of federally insured limits. To date, the Company has not experienced any losses on its cash and cash equivalents. As of December 31, 2015, the Company had $4.2 million in cash and cash equivalents and restricted cash held in banks in the United States in excess of the federally insured limits.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash As of December 31, 2015 and 2014, as required by the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company was required to maintain a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. Changes in the restricted cash balance were reflected as a financing activity in the consolidated statements of cash flows.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable The Company records accounts receivable at the invoiced amount when its products are shipped to customers or upon the completion of specific milestone billing requirements. The Company’s receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, aging of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based upon age or customer circumstances that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of December 31, 2015 and 2014, the allowance for doubtful accounts was $475,000 and $408,000, respectively. As of December 31, 2015, $4.2 million of eligible accounts receivable were pledged as collateral for the three-year asset-based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”). First Capital sold the FCC ABL to ACF Finco I LP (“Ares”) in May 2015, and the FCC ABL is hereinafter referred to as the “Ares ABL.” As of December 31, 2014, there were $5.4 million of eligible accounts receivable pledged as collateral for the Ares ABL.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market and have historically consisted of raw materials and purchased components and subsystems, work-in-process and finished lighting products, although inventories currently consist almost exclusively of finished lighting products due to the Company’s transition to contract manufacturers. The Company uses a standard costing methodology, which approximates actual cost on a weighted average basis to value its inventories and the Company reviews its standard costs of raw materials, work-in-process and finished goods inventory on a periodic basis to ensure that its inventories approximate current actual costs. Any purchase price variances related to labor and overhead that would indicate a loss on disposition of inventory is recorded to cost of goods sold in the statement of operations at the end of each reporting period. Market is determined based upon current sales transactions, less the cost of disposal. Work in process and finished lighting products include raw materials, labor and allocated overhead. Significant changes in the Company’s strategic plan, including changes in product mix, product demand, slow product adoption, rapid technological changes and new product introductions and enhancements could result in excess or obsolete inventory. The Company evaluates inventory levels and expected usage on a periodic basis to specifically identify obsolete, slow-moving or non-salable inventory based upon assumptions about future demand and market conditions. The write-down of excess and obsolete inventory based on this evaluation creates a new cost basis and is included in cost of goods sold. On a quarterly basis, the Company considers the need to record a lower of cost or market adjustment for its raw materials and finished goods inventory. The market value of finished goods is determined based upon current sales transactions, less the cost of disposal of the respective finished goods. The write-down of inventory to the lower of cost or market creates a new cost basis that cannot be marked up even if there are subsequent changes in the underlying facts and circumstances.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment under capital leases is stated at the present value of future minimum lease payments. Depreciation is provided using the straight-line method over the estimated economic lives of the assets, as follows: Estimated (years) Leasehold improvements 1 - 5 Office, furniture and equipment 2 - 5 Computer hardware and software 3 - 4 Tooling, production and test equipment 2 - 4 Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the minimum lease term or the estimated useful life of the assets. Expenditures for repairs and maintenance are charged to expense as incurred. The costs for major renewals and improvements are capitalized and depreciated over their estimated useful lives. All costs incurred for building of production tooling and molds are capitalized and amortized over the estimated useful life of the tooling set or mold.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets include patents and patents pending. Intangible assets with estimable useful lives are amortized over their respective useful lives on a straight-line basis. Finite–lived intangible assets are reviewed for impairment or obsolescence annually, or more frequently if events or changes in circumstance indicate that the carrying amount of an intangible asset may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-lived Assets Long lived assets, such as property, plant and equipment, and purchased intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third party independent appraisals, as considered necessary.
Derivatives, Policy [Policy Text Block]	Derivative Instruments The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. All derivatives are recorded at fair value on the consolidated balance sheets and changes in the fair value of such derivatives are measured in each period and are reported in other income (expense).
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Fair Value of Financial Instruments Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates. The Pegasus Commitment (as defined in Note 11 below) and all outstanding warrants other than the THD Warrant (as defined in Note 11 below) were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. The fair value of the THD Warrant is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until they have been earned for each year and these adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot, Inc . (“The Home Depot”). Once a portion of the THD Warrant vests it is recorded at its fair value at the end of each subsequent reporting period.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once these terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Fees and Costs Shipping and handling fees billed to customers are included in revenue. Shipping and handling costs associated with in-bound freight are included in cost of goods sold. Other shipping and handling costs are included in selling, distribution and administrative expenses and totaled $3.0 million, $1.8 million and $3.4 million for the years ended December 31, 2015, 2014 and 2013, respectively.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company expenses all research and development costs, including amounts for design prototypes and modifications made to existing prototypes, as incurred.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranties The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products and such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The following table summarizes changes in the warranty provision for the years ended December 31, 2015 and 2014 were as follows: Warranty provision as of December 31, 2013 $ 3,231,991 Additions to provision 4,752,626 Less warranty costs (3,195,147 ) Warranty provision as of December 31, 2014 4,789,470 Additions to provision 1,774,786 Less warranty costs (3,278,832 ) Warranty provision as of December 31, 2015 $ 3,285,424
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share Based Compensation The Company recognizes all employee stock based compensation as a cost in the financial statements based on the fair value of the share based compensation award. Equity classified awards are measured at the grant date fair value of the award. The Company estimates grant date fair value using the Black Scholes Merton option pricing model. As of December 31, 2015 and 2014, the Company had two share based compensation plans. The fair value of share based compensation awards, which historically have included stock options and restricted stock awards, is recognized as compensation expense in the statement of operations. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model. Option valuation methods require the input of highly subjective assumptions, including the expected stock price volatility. Measured compensation expense related to such option grants is recognized ratably over the vesting period of the related grants. Restricted stock awards are valued on the date of grant.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in the income tax provision.
Advertising Costs, Policy [Policy Text Block]	Advertising Advertising costs are included in selling, distribution and administrative expenses and are expensed when the advertising first takes place. The Company primarily promotes its product lines through print media and trade shows, including trade publications and promotional brochures. Advertising expenses were $43 ,000, $198,000 and $1.3 million for the years ended December 31, 2015, 2014 and 2013, respectively.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting The Company operates as a single segment under Accounting Standard Codification (“ASC”) 280-10-50, “Disclosures about Segments of an Enterprise and Related Information”. The Company’s chief operating decision maker reviews financial information at the enterprise level and makes decisions accordingly.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU 2014-09, which will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles and is intended to improve and converge the financial reporting requirements for revenue from contracts with customers with International Financial Reporting Standards (“IFRS”). The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. ASU 2014-09 also requires additional disclosures about the nature, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. ASU 2014-09 allows for both retrospective and prospective methods of adoption and is effective for periods beginning after December 15, 2016. In August 2015, the FASB issued ASU 2015-14 which provides a one-year deferral of the revenue recognition standard’s effective date. Public business entities are required to apply the revenue recognition standard to annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. Early application is permitted but not before the original effective date for public business entities (annual reporting periods beginning after December 15, 2016). The option to use either a retrospective or cumulative-effective transition method did not change. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2014-09 will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15 requiring management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. The standard also provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new guidance is effective for the annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2014-15 will have on its consolidated financial statements. In April 2015, the FASB issued ASU 2015-03 that intends to simplify the presentation of debt issuance costs. The new standard will more closely align the presentation of debt issuance costs under U.S. generally accepted accounting principles with the presentation under comparable IFRS standards. Debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. ASU 2015-03 is effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. The cost of issuing debt will no longer be recorded as a separate asset, except when incurred before receipt of the funding from the associated debt liability. Under current U.S. generally accepted accounting principles, debt issuance costs are reported on the balance sheet as assets and amortized as interest expense. The costs will continue to be amortized to interest expense using the effective interest method. Subsequent to the issuance of ASU 2015-03 the Securities and Exchange Commission staff made an announcement regarding the presentation of debt issuance costs associated with line-of-credit arrangements, which was codified by the FASB in ASU 2015-15. This guidance, which clarifies the exclusion of line-of-credit arrangements from the scope of ASU 2015-03, is effective upon adoption of ASU 2015-03. The Company has adopted both ASU 2015-03 and 2015-15. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2015-03 will have on its consolidated financial statements. In November 2015, the FASB issued ASU No 2015-17 to simplify the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in the balance sheet. The new guidance is effective for the annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the method of adoption and the impact that the adoption of ASU 2015-17 will have on its consolidated financial statements.

Note 2 - Summary of Significa31

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Estimated Useful Lives of Assets [Table Text Block]	Estimated (years) Leasehold improvements 1 - 5 Office, furniture and equipment 2 - 5 Computer hardware and software 3 - 4 Tooling, production and test equipment 2 - 4
Schedule of Product Warranty Liability [Table Text Block]	Warranty provision as of December 31, 2013 $ 3,231,991 Additions to provision 4,752,626 Less warranty costs (3,195,147 ) Warranty provision as of December 31, 2014 4,789,470 Additions to provision 1,774,786 Less warranty costs (3,278,832 ) Warranty provision as of December 31, 2015 $ 3,285,424

Note 4 - Fair Value Measureme32

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurement as of Decmber 31, 2015 Quoted Price in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 Assets (Recurring): Pegasus Commitment (1) $ - $ - $ 214,400 Liabilities (Recurring): Riverwood Warrants (2) $ - $ - $ 1,747,737 September 2012 Warrants (3) - - 214,400 Pegasus Warrant - - 966,000 THD Warrant - - 63,635 Medley Warrants - - 565,776 Pegasus Guaranty Warrants - - 615,261 $ - $ - $ 4,172,809
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Realized and unrealized Purchases, Balance gains (losses) sales, Transfers in Balance December 31, included issuances and or out of December 31, 2014 in net loss settlements Level 3 2015 Pegasus Commitment $ 720,000 $ (505,600 ) $ - $ - $ 214,400 Riverwood Warrants (2,352,027 ) 604,290 - - (1,747,737 ) September 2012 Warrants (720,000 ) 505,600 - - (214,400 ) Pegasus Warrant (1,300,000 ) 334,000 - - (966,000 ) THD Warrant (43,928 ) (19,707 ) - - (63,635 ) Medley Warrants (577,065 ) 11,289 - - (565,776 ) Pegasus Guaranty Warrants (643,924 ) 28,663 - - (615,261 ) Total $ (4,916,944 ) $ 958,535 $ - $ - $ (3,958,409 ) Realized and unrealized Purchases, Balance gains (losses) sales, Transfers in Balance December 31, included issuances and or out of December 31, 2013 in net loss settlements Level 3 2014 Pegasus Commitment $ 1,407,335 $ (687,335 ) $ - $ - $ 720,000 Riverwood Warrants (5,002,664 ) 2,650,637 - - (2,352,027 ) September 2012 Warrants (1,407,335 ) 687,335 - - (720,000 ) Pegasus Warrant (2,765,047 ) 1,465,047 - - (1,300,000 ) THD Warrant - 30,648 - (74,576 ) (43,928 ) Series J Warrants - (25,140,561 ) (12,505,739 ) 37,646,300 - Medley Warrants - 2,593,296 (3,170,361 ) - (577,065 ) Pegasus Guaranty Warrants - 2,692,650 (3,336,574 ) - (643,924 ) Total $ (7,767,711 ) $ (15,708,283 ) $ (19,012,674 ) $ 37,571,724 $ (4,916,944 )

Note 6 - Property and Equipme33

Note 6 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2015 December 31, 2014 Leasehold improvements $ 171,808 $ 158,421 Office furniture and equipment 290,348 293,183 Computer hardware and software 7,878,439 7,876,262 Tooling, production and test equipment 4,219,956 4,559,942 Trailers 45,996 45,996 Construction-in-process - 45,817 Total property and equipment 12,606,547 12,979,621 Accumulated depreciation (11,749,857 ) (10,329,506 ) Total property and equipment, net $ 856,690 $ 2,650,115

Note 7 - Intangible Assets an34

Note 7 - Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Cost, Less I mpairment Charges Accumulated Amortization Net Book Value Estimated Remaining Useful Life (years) December 31, 2015: Technology and intellectual property $ 3,332,556 $ (307,662 ) $ 3,024,894 0.9 to 20.0 December 31, 2014: Technology and intellectual property $ 2,796,580 $ (224,101 ) $ 2,572,479 2.7 to 20.0
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2016 $ 98,560 2017 98,560 2018 98,560 2019 98,560 2020 98,560 Thereafter 2,532,094 $ 3,024,894

Note 9 - Lines of Credit and 35

Note 9 - Lines of Credit and Note Payable (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	Borrowing, February 19, 2014 $ 30,500,000 Discount for Warrants (3,170,361 ) Discount for Commitment Fees (725,000 ) Accretion - Discounts 668,703 Paid in Kind - Interest Accretion 539,719 Balance, December 31, 2014 27,813,061 Accretion - Discounts 779,072 Paid in Kind - Interest Accretion 640,569 Balance, December 31, 2015 $ 29,232,702

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Holder Reason for Issuance Number of Underlying Shares Exercise Price Expiration Date Investors in rights offering Series D Warrants 1,192,048 $2.65 to $2.66 March 3, 2022 through April 19, 2022 The Home Depot Purchasing agreement 6,342,324 $ 0.95 December 31, 2016 through 2018 RW LSG Management Holdings LLC Riverwood Warrants 12,664,760 Variable May 25, 2022 Certain other investors Riverwood Warrants 5,427,751 Variable May 25, 2022 Cleantech Europe II (A) LP September 2012 Warrants 3,406,041 $ 0.72 September 25, 2022 Cleantech Europe II (B) LP September 2012 Warrants 593,959 $ 0.72 September 25, 2022 Portman Limited September 2012 Warrants 4,000,000 $ 0.72 September 25, 2022 Aquillian Investments LLC Private Placement Series H 830,508 $ 1.18 September 25, 2017 Pegasus Pegasus Warrant 10,000,000 Variable May 25, 2022 Series J Holders Series J Warrants 212,164,300 $ 0.001 January 3, 2019 through January 30, 2020 Medley Medley Warrants 10,000,000 $ 0.95 February 19, 2024 Pegasus Pegasus Guaranty Warrants 10,000,000 $ 0.50 February 19, 2024 Pegasus Series K Warrants 14,777,932 $ 0.12 December 31, 2025 291,399,623

Note 12 - Earnings (Loss) Per37

Note 12 - Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Third Quarter [Member]
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the Years Ended December 31, 2015 2014 2013 Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Controlling Stockholders Noncontrolling Stockholders Basic and diluted net income per share: Net loss from operations $ (20,449,368 ) $ (6,638,142 ) $ (52,134,928 ) $ (13,459,745 ) $ (74,506,560 ) $ (15,310,772 ) Deemed dividends related to the Series H, I and J Preferred Stock attributable to all shareholders (23,263,854 ) (7,551,762 ) (49,687,773 ) (12,827,960 ) (20,206,288 ) (4,152,304 ) Deemed dividends due to the issuance of Series K Preferred Stock as compensation for bond provided by controlling shareholders 1,147,766 (1,147,766 ) - - - - Deemed dividends due to the accretion of Series K Preferred Stock (14,312,298 ) (4,645,966 ) Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders - - 570,574 (570,574 ) - - Undistributed net loss $ (56,877,755 ) $ (19,983,635 ) $ (101,252,127 ) $ (26,858,279 ) $ (94,712,848 ) $ (19,463,076 ) Basic and diluted weighted average number of common shares outstanding 303,742,731 98,598,998 232,409,186 60,001,396 170,662,220 35,070,340 Basic and diluted net loss per common share: $ (0.19 ) $ (0.20 ) $ (0.44 ) $ (0.45 ) $ (0.55 ) $ (0.55 )

Note 14 - Equity Based Compen38

Note 14 - Equity Based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2014 44,281,364 $ 0.56 Granted 24,416,277 0.14 Exercised - - Forfeited or expired (8,570,994 ) 1.07 Outstanding as of December 31, 2015 60,126,647 $ 0.31 8.35 $ - Vested or expected to vest as of December 31, 2015 48,712,673 $ 0.35 8.16 $ - Exercisable as of December 31, 2015 17,577,168 $ 0.64 6.46 $ -
Schedule of Stock Options Roll Forward [Table Text Block]	Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Average Remaining Contractual Term Weighted Average Exercise Price Number Weighted Average Exercise Price $0.11 - $0.11 14,024,257 9.80 $ 0.11 2,326,445 $ 0.11 $0.13 - $0.13 3,132,020 9.88 0.13 - - $0.18 - $0.18 27,800,000 8.77 0.18 6,950,000 0.18 $0.20 - $1.00 12,091,998 6.42 0.55 5,714,248 0.89 $1.04 - $4.35 3,069,122 4.01 1.70 2,577,225 1.77 $7.40 - $7.40 3,000 1.11 7.40 3,000 7.40 $10.80 - $10.80 6,250 1.59 10.80 6,250 10.80 Total 60,126,647 8.35 $ 0.31 17,577,168 $ 0.64
Schedule of Share-based Compensation, Activity [Table Text Block]	For the Years Ended December 31, 2015 2014 2013 Weighted average grant date fair value per share of options $ 0.11 $ 0.14 $ 0.39 Total intrinsic value of options exercised $ - $ - $ -
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	Number of Shares Weighted Average Grant Date Fair Value Unnvested as of December 31, 2014 2,080,342 $ 0.38 Granted 2,033,905 0.20 Vested (2,221,177 ) 0.36 Forfeited (1,693,070 ) 0.21 Unvested as of December 31, 2015 200,000 $ 0.20
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the Years Ended December 31, Variable Ranges 2015 2014 2013 Exercise price $0.11 - $0.24 $0.18 - $0.50 $0.44 - $0.70 Fair market value of the underlying stock on date of grant $0.11 - $0.24 $0.18 - $0.42 $0.38 - $0.64 Stock Option Grants: Risk-free interest rate 1.31% - 1.68% 0.209% - 2.07% 1.03% - 2.00% Expected life, in years 5.06 - 6.25 1.75 - 6.25 6.00 - 6.25 Expected volatility 91.86% - 102.48% 67.32% - 100.46% 99.51% - 101.82% Expected dividend yield 0.0% 0.0% 0.0% Expected forfeiture rate 14.93% 19.19% 7.49% Fair value per share $0.12 - $0.28 $0.12 - $0.28 $0.08 - $0.52

Note 15 - Restructuring Expen39

Note 15 - Restructuring Expense (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Restructuring and Related Costs [Table Text Block]	For the Years Ended December 31, 2015 2014 2013 Broad based reduction of facilities and personnel (1) $ 1,883,326 $ 3,314,251 $ 4,479,076 Mexico Closing (2) - - 102,688 Organization Optimization Initiative (3) - 114,277 77,061 Total $ 1,883,326 $ 3,428,528 $ 4,658,825
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Workforce Excess Other Reduction Facilities Exit Costs Total Accrued liability as of December 31, 2013 $ 699,832 $ - $ 276,956 $ 976,788 Charges 2,496,184 311,269 122,054 2,929,507 Payments (2,236,776 ) - (218,170 ) (2,454,946 ) Accrued liability as of December 31, 2014 $ 959,240 $ 311,269 $ 180,840 $ 1,451,349 Charges 297,770 - - 297,770 Payments (1,117,625 ) (69,776 ) (167,960 ) (1,355,361 ) Accrued liability as of December 31, 2015 $ 139,385 $ 241,493 $ 12,880 $ 393,758

Note 16 - Income Taxes (Tables)

Note 16 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the Years Ended December 31, 2015 2014 2013 Loss before taxes Domestic $ (26,652,135 ) $ (64,343,390 ) $ (86,599,121 ) Foreign (418,873 ) (1,251,283 ) (3,218,211 ) Total $ (27,071,008 ) $ (65,594,673 ) $ (89,817,332 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the Years Ended December 31, 2015 2014 2013 Loss before taxes $ (27,071,008 ) $ (65,594,673 ) $ (89,817,332 ) Income tax benefit applying United States federal statutory rate of 34% (9,204,143 ) $ (22,302,189 ) $ (30,537,893 ) State taxes, net of federal benefit (776,264 ) (1,183,397 ) (1,674,412 ) Permanent differences Derivative fair value adjustment 203,498 5,359,878 (1,323,618 ) Other 26,037 - 40,669 Increase in valuation allowance 4,763,028 30,513,501 31,336,114 Change in effective tax rate - United States (2,910,847 ) (2,679,697 ) 1,597,640 Change in effective tax rate - foreign - - - Expiration/true-up of NOL's 7,840,050 (10,236,058 ) 110,950 Rate difference between United States federal statutory rate and Netherlands statutory rate 58,642 175,180 450,550 Other - 352,782 - Income tax expense (benefit) $ - $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2015 2014 Deferred income tax assets Net operating loss carryforwards $ 188,129,680 $ 181,983,692 Stock based compensation 9,825,558 8,957,780 Inventories 2,569,531 2,864,989 Warranty liability 1,235,724 1,745,093 Fixed asset impairment 616,709 1,168,224 Accrued legal fees 945,664 552,889 Goodwill impairment on asset acquisition 459,591 871,229 Accrued rebates 843,340 448,481 Accounts receivable 165,495 138,221 Accrued compensation 154,130 357,750 Charitable contribution carryforward 67,682 56,979 Depreciation 66,987 66,775 Accrued Expenses 55,691 - India start-up costs 33,136 32,645 Reserve for losses on non-cancelable purchase commitments - 172,110 Accrued Florida use tax - 830 Total deferred income tax assets 205,168,916 199,417,687 Less: valuation allowance (203,452,854 ) (198,689,826 ) Net deferred tax assets $ 1,716,063 $ 727,861 Deferred income tax liabilities Stock losses $ (171,976 ) $ (169,409 ) Interest Expense (14,004 ) Loss on disposal of long-lived assets (1,530,083 ) (558,452 ) Total deferred income tax liabilities (1,716,063 ) (727,861 ) Net deferred tax liabilities $ - $ -
Schedule of Operating Loss Carry Forward Expiration [Table Text Block]	Year of Expiration United States Net Operating Tax Loss Carryforwards The Netherlands Net Operating Tax Loss Carryforwards 2016 - 3,869,995 2017 - 4,265,206 2018 5,357,429 4,692,440 2019 2,293,432 908,706 2020 1,473,066 908,568 2021 2,769,043 2,027,511 2022 1,840,300 - 2023 2,031,270 - 2024 3,353,481 - 2025 2,293,432 - 2026 2,293,432 - 2027 9,937,230 - 2028 29,631,134 - 2029 33,916,312 - 2030 50,887,617 2031 67,057,312 2032 90,683,320 2033 82,316,468 2034 59,822,398 2035 28,057,263 Total $ 476,013,939 $ 16,672,426

Note 18 - Commitments and Con41

Note 18 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Amount 2016 $ 398,461 2017 317,777 2018 276,705 2019 276,705 2020 - Thereafter - $ 1,269,648

Note 20 - Quarterly Financial42

Note 20 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Quarterly Financial Information [Table Text Block]	2015 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Revenue $ 19,371,545 $ 23,270,363 $ 19,587,399 $ 17,520,465 Gross margin 2,930,248 3,416,535 5,223,665 (369,184 ) Net income (loss) (13,601,090 ) (2,444,313 ) 269,344 (11,311,451 ) Basic and diluted net loss per weighted average common share attributable to controlling shareholders $ (0.07 ) $ (0.01 ) $ (0.04 ) $ (0.03 ) Basic and diluted net loss per weighted average common share attributable to noncontrolling shareholders $ (0.07 ) $ (0.01 ) $ (0.04 ) $ (0.03 ) 2014 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Revenue $ 25,925,841 $ 19,827,864 $ 23,089,356 $ 22,441,799 Gross margin 2,690,495 1,119,562 3,420,353 (3,648,278 ) Net loss (40,093,963 ) (11,628,516 ) (2,102,576 ) (11,769,618 ) Basic and diluted net loss per weighted average common share attributable to controlling shareholders $ (0.33 ) $ (0.04 ) $ (0.04 ) $ (0.09 ) Basic and diluted net loss per weighted average common share attributable to noncontrolling shareholders $ (0.35 ) $ (0.04 ) $ (0.04 ) $ (0.09 )

Note 21 - Valuation and Quali43

Note 21 - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Summary of Valuation Allowance [Table Text Block]	Valuation and qualifying accounts deducted from the assets to which they apply Balance as of Beginning of Period Currency Translation Adjustments Additions Charged to Costs and Expenses Additions Charged (Credited) to Other Accounts Deductions from Allowances Balance as of End of Period Allowance for doubtful accounts 2015 $ 408,047 (1,097 ) 83,105 - (15,031 ) $ 475,024 2014 $ 509,561 (8,574 ) 103,792 - (196,732 ) $ 408,047 2013 $ 1,188,366 7,381 279,757 - (965,943 ) $ 509,561 Provision for purchase commitments 2015 $ 540,227 (1,260 ) 115,926 (643,648 ) (11,245 ) $ - 2014 $ 1,629,806 (13,556 ) 507,257 (1,217,878 ) (365,402 ) $ 540,227 2013 $ 5,678,992 - 1,283,444 (4,562,550 ) (770,080 ) $ 1,629,806

Note 2 - Summary of Significa44

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Feb. 19, 2014	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Medley Term Loan [Member]
Debt Instrument, Term	5 years	5 years	5 years
Minimum [Member] | Medley Term Loan [Member]
Restricted Cash and Cash Equivalents, Current		$ 3,000,000	$ 3,000,000
Ares ABL [Member]
Debt Instrument, Collateral Amount		4,200,000	5,400,000
Selling, Distribution and Administrative Expenses [Member]
Shipping, Handling and Transportation Costs		3,000,000	1,800,000	$ 3,400,000
Cash Equivalents, at Carrying Value		$ 0	$ 0
Number of Share-Based Compensation Plans		2	2
Restricted Cash and Cash Equivalents, Current		$ 3,000,000
CashAndCashEquivalentsAndRestrictedCashAtCarryingValue		4,200,000
Allowance for Doubtful Accounts Receivable		$ 475,000	$ 408,000
Products Warranty Period		5 years
Advertising Expense		$ 43,000	$ 198,000	$ 1,300,000

Note 2 - Estimated Economic Liv

Note 2 - Estimated Economic Lives of the Assets (Details)	12 Months Ended
	Dec. 31, 2015
Leasehold Improvements [Member] | Minimum [Member]
Leasehold improvements	1 year
Leasehold Improvements [Member] | Maximum [Member]
Leasehold improvements	5 years
Office Furniture and Equipment [Member] | Minimum [Member]
Leasehold improvements	2 years
Office Furniture and Equipment [Member] | Maximum [Member]
Leasehold improvements	5 years
Computer Hardware and Software [Member] | Minimum [Member]
Leasehold improvements	3 years
Computer Hardware and Software [Member] | Maximum [Member]
Leasehold improvements	4 years
Tooling, Production and Test Equipment [Member] | Minimum [Member]
Leasehold improvements	2 years
Tooling, Production and Test Equipment [Member] | Maximum [Member]
Leasehold improvements	4 years

Note 2 - Summary of Warranty Pr

Note 2 - Summary of Warranty Provision (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Warranty provision	$ 4,789,470	$ 3,231,991
Additions to provision	1,774,786	4,752,626
Less warranty costs	(3,278,832)	(3,195,147)
Warranty provision	$ 3,285,424	$ 4,789,470

Note 3 - Liquidity and Capita47

Note 3 - Liquidity and Capital Resources (Details Textual) - USD ($)	Dec. 07, 2015	Sep. 30, 2015	Sep. 11, 2015	Jan. 30, 2015	Feb. 19, 2014	Dec. 31, 2015	Dec. 31, 2014	Apr. 25, 2014	Dec. 31, 2013	Dec. 31, 2012
Series J Preferred Stock [Member] | Series J Redeemable Convertible Preferred Stock [Member] | Holdings III [Member ]
Share Price			$ 1,000	$ 1,000
Stock Issued During Period, Shares, New Issues		62	10,000	11,525
Proceeds from Issuance of Redeemable Preferred Stock		$ 21,600,000
Convertible Preferred Stock, Shares Issued upon Conversion			1
Series J Redeemable Convertible Preferred Stock [Member]
Share Price						$ 1,000	$ 1,000		$ 1,000
Series K Preferred Stock [Member]
Share Price						$ 1,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						735
Convertible Preferred Stock, Shares Issued upon Conversion						1
Series K Warrant [Member] | Pegasus Fund IV [Member]
Security Units Issued	20,106.03					20,106.03
Series J Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			2,650	2,650			2,650
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.001	$ 0.001		$ 0.001	$ 0.001
Medley Term Loan [Member]
Debt Instrument, Term					5 years	5 years	5 years
Line of Credit Facility, Maximum Borrowing Capacity					$ 30,500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					5,000,000
Ares ABL [Member]
Debt Instrument, Term						3 years
Line of Credit Facility, Maximum Borrowing Capacity								$ 22,500,000
Line of Credit, Current						$ 6,900,000
Line of Credit Facility, Remaining Borrowing Capacity						6,300,000
Pegasus Commitment [Member]
Other Commitment						5,250,000
Geveran Case [Member]
Loss Contingency, Damages Sought, Value						25,000,000
Appeal Bond, Amount						20,100,000
Retained Earnings (Accumulated Deficit)						(827,416,083)	$ (800,328,573)
Stockholders' Equity Attributable to Parent						(551,377,265)	(487,056,183)		$ (410,849,963)	$ (304,497,378)
Cash and Cash Equivalents, at Carrying Value						647,526	$ 1,609,297		$ 11,195,412	$ 15,834,077
Restricted Cash and Cash Equivalents, Current						$ 3,000,000
Common Stock, Par or Stated Value Per Share						$ 0.001	$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						291,399,623
Line of Credit, Current						$ 6,862,629	$ 6,368,793
Preferred Stock, Redemption Amount						532,200,000
Debt, Long-term and Short-term, Combined Amount						36,100,000
Loss Contingency, Damages Sought, Value						$ 25,000,000

Note 4 - Fair Value Measureme48

Note 4 - Fair Value Measurements (Details Textual) - shares	Dec. 31, 2015	Sep. 30, 2012	May. 25, 2012
Riverwood Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			18,092,511
September Two Thousand Twelve Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		8,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	291,399,623

Note 4 - Financial Assets and L

Note 4 - Financial Assets and Liabilities Accounted For at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member]	Dec. 31, 2015USD ($)
Fair Value, Inputs, Level 1 [Member] | Pegasus Commitment [Member]
Pegasus Commitment (1)		[1]
Fair Value, Inputs, Level 1 [Member] | Riverwood Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring		[2]
Fair Value, Inputs, Level 1 [Member] | September Two Thousand Twelve Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring		[3]
Fair Value, Inputs, Level 1 [Member] | Pegasus Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | THD Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | Medley Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member] | Pegasus Guaranty Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | Pegasus Commitment [Member]
Pegasus Commitment (1)		[1]
Fair Value, Inputs, Level 2 [Member] | Riverwood Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring		[2]
Fair Value, Inputs, Level 2 [Member] | September Two Thousand Twelve Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring		[3]
Fair Value, Inputs, Level 2 [Member] | Pegasus Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | THD Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | Medley Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member] | Pegasus Guaranty Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure, Recurring
Fair Value, Inputs, Level 3 [Member] | Pegasus Commitment [Member]
Pegasus Commitment (1)	$ 214,400	[1]
Fair Value, Inputs, Level 3 [Member] | Riverwood Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	1,747,737	[2]
Fair Value, Inputs, Level 3 [Member] | September Two Thousand Twelve Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	214,400	[3]
Fair Value, Inputs, Level 3 [Member] | Pegasus Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring	966,000
Fair Value, Inputs, Level 3 [Member] | THD Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring	63,635
Fair Value, Inputs, Level 3 [Member] | Medley Warrant [Member]
Liabilities, Fair Value Disclosure, Recurring	565,776
Fair Value, Inputs, Level 3 [Member] | Pegasus Guaranty Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	615,261
Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure, Recurring	$ 4,172,809
[1]	On September 25, 2012, the Company entered into a Commitment Agreement with Pegasus IV, pursuant to which the Company is obligated to buy from Pegasus IV or its affiliates shares of Common Stock equal to the number of shares, if any, for which the September 2012 Warrants (as defined below) are exercised, up to an aggregate number of shares of Common Stock equal to the aggregate number of shares of Common Stock underlying all of the September 2012 Warrants.
[2]	On May 25, 2012, the Company issued a warrant to purchase 18,092,511 shares of Common Stock to Riverwood Management as consideration for services provided in connection with an offering of Convertible Preferred Stock (the "Riverwood Warrant"). Riverwood Management has since partially assigned such warrant to several of its affiliates. The warrants, as amended or assigned from time to time, are referred to herein as the "Riverwood Warrants."
[3]	In September 2012, in connection with an offering of Convertible Preferred Stock, the Company issued warrants to purchase an aggregate of 8,000,000 shares of Common Stock (the "September 2012 Warrants") to Portman, Cleantech Europe II (A) L.P. ("Cleantech A" and Cleantech Europe II (B) L.P. ("Cleantech A" and Cleantech Europe II (B) L.P. )Cleantech B" and together with Cleantech A, "Zouk").

Note 4 - Reconciliation of Begi

Note 4 - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Pegasus Commitment [Member]
Beginning balance	$ 720,000	$ 1,407,335
Realized and unrealized gains included in net loss	$ (505,600)	$ (687,335)
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ 214,400	$ 720,000
Riverwood Warrants [Member]
Beginning balance	(2,352,027)	(5,002,664)
Realized and unrealized gains included in net loss	$ 604,290	$ 2,650,637
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ (1,747,737)	$ (2,352,027)
September Two Thousand Twelve Warrants [Member]
Beginning balance	(720,000)	(1,407,335)
Realized and unrealized gains included in net loss	$ 505,600	$ 687,335
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ (214,400)	$ (720,000)
Pegasus Warrant [Member]
Beginning balance	(1,300,000)	(2,765,047)
Realized and unrealized gains included in net loss	$ 334,000	$ 1,465,047
Purchases, sales, issuances and settlements
Transfers in or out of Level 3
Ending balance	$ (966,000)	$ (1,300,000)
THD Warrant [Member]
Beginning balance	(43,928)
Realized and unrealized gains included in net loss	$ (19,707)	$ 30,648
Purchases, sales, issuances and settlements
Transfers in or out of Level 3		$ (74,576)
Ending balance	$ (63,635)	$ (43,928)
Medley Warrant [Member]
Beginning balance	(577,065)
Realized and unrealized gains included in net loss	$ 11,289	$ 2,593,296
Purchases, sales, issuances and settlements		$ (3,170,361)
Transfers in or out of Level 3
Ending balance	$ (565,776)	$ (577,065)
Series J Warrants [Member]
Beginning balance
Realized and unrealized gains included in net loss		$ (25,140,561)
Purchases, sales, issuances and settlements		(12,505,739)
Transfers in or out of Level 3		$ 37,646,300
Ending balance
Pegasus Guaranty Warrants [Member]
Beginning balance	$ (643,924)
Realized and unrealized gains included in net loss	$ 28,663	$ 2,692,650
Purchases, sales, issuances and settlements		$ (3,336,574)
Transfers in or out of Level 3
Ending balance	$ (615,261)	$ (643,924)
Beginning balance	(4,916,944)	(7,767,711)
Realized and unrealized gains included in net loss	$ 958,535	(15,708,283)
Purchases, sales, issuances and settlements		(19,012,674)
Transfers in or out of Level 3		37,571,724
Ending balance	$ (3,958,409)	$ (4,916,944)

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Inventory Write-down	$ 3,786,113	$ 4,722,436	$ 11,350,469
Inventory Valuation Reserves	6,900,000	7,900,000
Provision for Other Losses	115,926	507,257	$ 2,347,905
Provision for Losses on Purchase Commitments Accrued	$ 0	$ 540,000

Note 6 - Property and Equipme52

Note 6 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Asset Impairment Charges	$ 0	$ 636,636	$ 2,420,132
Depreciation	$ 1,900,000	$ 3,300,000	$ 8,700,000

Note 6 - Summary of Property an

Note 6 - Summary of Property and Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Leasehold Improvements [Member]
Total property and equipment	$ 171,808	$ 158,421
Office Furniture and Equipment [Member]
Total property and equipment	290,348	293,183
Computer Hardware and Software [Member]
Total property and equipment	7,878,439	7,876,262
Tooling, Production and Test Equipment [Member]
Total property and equipment	4,219,956	4,559,942
Trailers [Member]
Total property and equipment	$ 45,996	45,996
Construction in Progress [Member]
Total property and equipment		45,817
Total property and equipment	$ 12,606,547	12,979,621
Accumulated depreciation	(11,749,857)	(10,329,506)
Total property and equipment, net	$ 856,690	$ 2,650,115

Note 7 - Intangible Assets an54

Note 7 - Intangible Assets and Goodwill (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Impairment of Intangible Assets, Finite-lived	$ 0	$ 0	$ 0
Amortization of Intangible Assets	$ 84,000	$ 64,000	$ 40,000

Note 7 - Summary of Intangible

Note 7 - Summary of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Technology and Intellectual Property [Member] | Minimum [Member]
Technology and intellectual property	328 days	2 years 255 days
Technology and Intellectual Property [Member] | Maximum [Member]
Technology and intellectual property	20 years	20 years
Technology and Intellectual Property [Member]
Technology and intellectual property	$ 3,332,556	$ 2,796,580
Technology and intellectual property	(307,662)	(224,101)
Technology and intellectual property	3,024,894	2,572,479
Technology and intellectual property	$ 3,024,894	$ 2,572,479

Note 7 - Summary of Expected Am

Note 7 - Summary of Expected Amortization Expense (Details)	Dec. 31, 2015USD ($)
2,016	$ 98,560
2,017	98,560
2,018	98,560
2,019	98,560
2,020	98,560
Thereafter	2,532,094
	$ 3,024,894

Note 8 - Debt Issuance Costs (D

Note 8 - Debt Issuance Costs (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Assets [Member]
Deferred Finance Costs, Current, Net		$ 1,800,000
Ares ABL and Medley [Member]
Debt Issuance Cost		6,000,000
Pegasus Guaranty [Member]
Debt Issuance Cost	$ 2,800,000
Debt Issuance Cost		3,300,000	$ 3,200,000
Amortization of Financing Costs		$ 1,528,761	$ 1,586,204	$ 506,745

Note 9 - Lines of Credit and 58

Note 9 - Lines of Credit and Note Payable (Details Textual) - USD ($)	Sep. 11, 2015	Feb. 19, 2014	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Apr. 25, 2014	Sep. 21, 2011
Ares ABL [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	5.50%			5.50%
Ares ABL [Member] | Accounts Receivable [Member]
Debt Instrument, Collateral Amount				$ 3,500,000
Ares ABL [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 22,500,000
Line of Credit, Current			$ 6,900,000		$ 6,900,000
Line of Credit Facility, Remaining Borrowing Capacity							$ 6,300,000
Change in Interest Margin Payable	1.50%
Debt Instrument, Collateral Amount			5,400,000	4,200,000	5,400,000
Line of Credit Facility, Eligible Collateral Inventory				$ 10,000,000
Debt Instrument, Interest Rate, Effective Percentage				5.74%
Medley Capital Corporation [Member] | London Interbank Offered Rate (LIBOR) [Member] | Medley Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate		12.00%
Medley Capital Corporation [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		10.50%
Medley Capital Corporation [Member] | Medley Term Loan [Member] | Commitment Fees [Member] | Medley Warrant [Member]
Accretion of Discount				$ 779,072	668,703
Debt Instrument, Increase, Accrued Interest				640,569	539,719
Medley Capital Corporation [Member] | Medley Term Loan [Member] | Interest Expense [Member]
Amortization of Debt Discount (Premium)				$ 640,569	539,719
Medley Capital Corporation [Member] | Medley Term Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage				12.41%
Notes Payable		$ 30,500,000
Accrued Interest Rate of Loan		2.00%
Restricted Cash and Cash Equivalents, Current				$ 3,000,000
Medley Capital Corporation [Member] | Medley Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.95
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				10,000,000
Medley Capital Corporation [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 22,500,000
Wells Fargo ABL [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 50,000,000
Ares Capital [Member]
Standby Letter of Credit								$ 25,000,000
Medley Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 30,500,000
Amortization of Debt Discount (Premium)			668,703	779,072
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		5,000,000
Amendment to Medley Term Loan [Member]
Term Loan Covenants, Cash Proceeds from Offering to be Used in EBITDA Calcuation	$ 10,000,000
Medley Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.95
Interest Rate Derivative Liabilities, at Fair Value		$ 3,200,000
Fair Value Adjustment of Warrants				11,000	2,600,000
Pegasus Guaranty [Member] | Implied Interest Rate Analysis [Member]
Debt Issuance Cost		$ 2,800,000
Pegasus Guaranty [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.50
Interest Rate Derivative Liabilities, at Fair Value		$ 3,300,000
Fair Value Adjustment of Warrants				29,000	2,700,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		5,000,000
Dividends, Preferred Stock, Stock		$ 571,000
Line of Credit, Current			$ 6,368,793	6,862,629	6,368,793
Restricted Cash and Cash Equivalents, Current				3,000,000
Accretion of Discount				779,072	668,703	$ 0
Debt Instrument, Increase, Accrued Interest				(640,569)	(539,719)	$ 0
Debt Issuance Cost				$ 3,300,000	$ 3,200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				291,399,623

Note 9 - Activity in the Medley

Note 9 - Activity in the Medley Term Loan (Details)	10 Months Ended	12 Months Ended
	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)
Medley Term Loan [Member]
Balance	$ 30,500,000	$ 27,813,061
Discount for Warrants	(3,170,361)
Discount for Commitment Fees	(725,000)
Amortization of Debt Discount (Premium)	668,703	779,072
Paid in Kind - Interest Accretion	539,719	640,569
Balance	27,813,061	29,232,702
Balance		27,813,061
Balance	$ 27,813,061	$ 29,232,702

Note 10 - Redeemable Preferre60

Note 10 - Redeemable Preferred Stock (Details Textual)	Dec. 07, 2015$ / sharesshares	Sep. 11, 2013USD ($)$ / sharesshares	Jan. 31, 2014shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2012USD ($)shares	Sep. 11, 2015shares	Jan. 30, 2015$ / sharesshares	Aug. 28, 2014shares	Feb. 19, 2014$ / shares	Jan. 09, 2014shares	Jan. 03, 2014shares
Series H Redeemable Convertible Preferred Stock [Member]
Preferred Stock, Shares Issued							60,705
Series I Redeemable Convertible Preferred Stock [Member]
Preferred Stock, Shares Issued							6,364
Series H and Series I Preferred Stock [Member]
Deemed Dividends | $						$ 14,400,000
Series J Redeemable Convertible Preferred Stock [Member] | Holdings II [Member]
Preferred Units, Issued					6,000								6,000
Stock Issued During Period, Shares, New Issues						13,657
Series J Redeemable Convertible Preferred Stock [Member] | PCA Holdings [Member]
Preferred Units, Issued					14,000					8,000		4,000	2,000
Stock Issued During Period, Shares, New Issues						2,500
Series J Redeemable Convertible Preferred Stock [Member] | Riverwood Holdings [Member]
Preferred Units, Issued					2,860
Stock Issued During Period, Shares, New Issues						2,394
Series J Redeemable Convertible Preferred Stock [Member] | Other Accredited Investors [Member]
Preferred Units, Issued					45
Stock Issued During Period, Shares, New Issues						1,449
Series J Redeemable Convertible Preferred Stock [Member] | Serengeti [Member]
Preferred Units, Issued					13,000
Series J Redeemable Convertible Preferred Stock [Member] | Zouk [Member]
Preferred Units, Issued					2,570							2,570
Series J Redeemable Convertible Preferred Stock [Member] | Holdings III [Member ]
Preferred Units, Issued								10,000	11,525
Proceeds from Issuance of Preferred Stock and Preference Stock | $				$ 21,600,000
Preferred Stock Exchanged for Other Securities, Shares Issued				21,587
Shares Issued, Price Per Share | $ / shares				$ 1,000					$ 1,000
Series J Redeemable Convertible Preferred Stock [Member]
Preferred Stock, Shares Issued				80,062
Share Price | $ / shares				$ 1,000	$ 1,000	$ 1,000
Preferred Stock Conversion Price Per Share | $ / shares				$ 0.95
Preferred Units, Issued					38,475	20,000
Proceeds from Issuance of Preferred Stock and Preference Stock | $					$ 38,500,000	$ 20,000,000
Series K Warrant [Member] | Pegasus Fund IV [Member]
Shares Issued, Price Per Share | $ / shares	$ 1,000
Security Units Issued	20,106.03			20,106.03
Series K Preferred Stock [Member] | Mezzanine Equity [Member]
Deemed Dividends | $				$ 19,000,000
Preferred Stock, Redemption Amount | $				$ 1,100,000
Series K Preferred Stock [Member]
Preferred Stock, Shares Issued				20,106	0
Preferred Stock, Par or Stated Value Per Share | $ / shares				$ 0.001	$ 0.001
Share Price | $ / shares				1,000
Shares Issued, Price Per Share | $ / shares				1,000
Private Placement Series H [Member] | Acquillian Investments LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1.18		$ 1.18
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				830,508
Medley Warrant [Member] | Medley Capital Corporation [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.95
Medley Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 0.95
Pegasus Warrant [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross		10,000,000				10,000,000
Series J Securities [Member] | Holdings II [Member]
Preferred Stock Exchanged for Other Securities, Shares Issued			13,657
Series J Securities [Member] | PCA Holdings [Member]
Preferred Stock Exchanged for Other Securities, Shares Issued			2,500
Series J Securities [Member] | Riverwood Holdings [Member]
Preferred Stock Exchanged for Other Securities, Shares Issued			2,394
Series J Securities [Member] | Other Initial Series J Investors [Member]
Preferred Stock Exchanged for Other Securities, Shares Issued			1,449
Series H and Series I Preferred Stock [Member]
Deemed Dividends | $							$ 203,600,000
Series J Redeemable Convertible Preferred Stock [Member]
Deemed Dividends | $				$ 117,700,000
SeriesJ Issuance [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				212,164,300
Common Stock [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross						1,854,507
Amount of Indebtness Without Consent of Related Party | $		$ 10,000,000
Amount of Increased Indebtness Without Consent of Related Party | $		$ 50,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 1,000
Deemed Dividends | $				$ 20,106,030	$ 0	$ 0
Number of Times Liquidation Amount Multiplied				2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				291,399,623
Preferred Stock, Redemption Amount | $				$ 532,200,000

Note 11 - Stockholders' Equit61

Note 11 - Stockholders' Equity (Details Textual) - USD ($)	Nov. 19, 2015	Mar. 24, 2015	Aug. 28, 2014	Jun. 12, 2014	Mar. 25, 2014	Sep. 11, 2013	Aug. 14, 2013	Jan. 13, 2011	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 11, 2015	Jan. 30, 2015	Sep. 30, 2012	May. 25, 2012
Series D Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 2.65
Series D Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 2.67
Series D Warrants [Member]
Shares Issuable Pursuant to Warrant Vested									2,114,108	0	2,114,108	0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										1,192,048
Total Number of Warrants Vested										6,342,324
Number of Shares Remaining to Vest										2,114,108
THD Warrant [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																18,092,511
THD Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								5,000,000		6,342,324
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 2		$ 0.95
Warrant Shares of Common Stock Eligible for Vesting Each Year								1,000,000
Exercise Percent of Warrants																5.00%
Equity Value of Company Exceeds																$ 500,000,000
Fair Value Adjustment of Warrants										$ 604,000	$ 2,700,000	$ 3,000,000
Increase (Decrease) in Revenue from Change in Fair Market Value of Warrants										(64,000)	(103,000)	0
Change in Fair Value of Previously Vested Portion of Warrant										83,000
September 2012 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 0.72
Fair Value Adjustment of Warrants										506,000	687,000	47,000
Pegasus Commitment [Member]
Fair Value Adjustment of Warrants										506,000	687,000	47,000
Pegasus Warrant [Member] | Stockholders' Equity, Total [Member]
Concentration Risk, Percentage						2.764%
Pegasus Warrant [Member]
Equity Value of Company Exceeds						$ 580,000,000
Fair Value Adjustment of Warrants										$ 334,000	$ 1,500,000	$ 935,000
Stock Issued During Period, Shares, Share-based Compensation, Gross						10,000,000						10,000,000
Series J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001
Fair Value Adjustment of Warrants											$ (25,100,000)
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									2,650		2,650		2,650	2,650
Warrants and Rights Outstanding									$ 12,500,000		$ 12,500,000
Series K Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.12
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right										735
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Calcelled in Period	1,459,521
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	3,132,020
Allocated Share-based Compensation Expense										$ 79,000	670,000	$ 725,000
Employee Stock Option [Member] | Director [Member]
Allocated Share-based Compensation Expense										280,000	0	$ 21,000
Scientific Advisory Board [Member]
Restricted Stock or Unit Expense										37,000	64,000
Common Stock [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross												1,854,507
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		2,033,905	78,360	110,685	1,484,931				150,137
Restricted Stock or Unit Expense										121,000	730,000	$ 891,000
Allocated Share-based Compensation Expense										$ 358,671	$ 669,639	$ 745,610
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										291,399,623
Percentage of Gross Product Order										20.00%
Long Term Purchase Commitment Additional Extension Time Period							3 years			1 year
Long Term Purchase Commitment Term										3 years
Tranche of Warrants Expiration Number										2,114,107
Threshold Equity for Exercise of Warrant										$ 580,000,000

Note 11 - Warrants Outstanding

Note 11 - Warrants Outstanding for Purchase of Common Stock (Details)	Dec. 31, 2015$ / sharesshares
Investors in Rights Offering [Member] | Series D Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.65
Investors in Rights Offering [Member] | Series D Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.66
Investors in Rights Offering [Member] | Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	1,192,048
The Home Depot [Member] | Purchasing Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	6,342,324
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.95
Series D Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	2.65
Series D Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.67
Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	1,192,048
Riverwood Warrants [Member] | RW LSG Management Holdings LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	12,664,760
Riverwood Warrants [Member] | Certain Other Investors [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	5,427,751
September Two Thousand Twelve Warrants [Member] | Cleantech A [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	3,406,041
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.72
September Two Thousand Twelve Warrants [Member] | Cleantech B [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	593,959
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.72
September Two Thousand Twelve Warrants [Member] | Portman [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	4,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.72
Private Placement Series H [Member] | Acquillian Investments LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	830,508
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.18
Pegasus Warrant [Member] | Pegasus Capital [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.50
Series J Warrants [Member] | Series J Holders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	212,164,300
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.001
Series J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.001
Medley Warrant [Member] | Medley Capital Corporation [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.95
Pegasus Guaranty Warrants [Member] | Pegasus Capital [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	10,000,000
Series K Warrant [Member] | Pegasus Capital [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	14,777,932
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.12
Series K Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.12
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	291,399,623

Note 12 - Earnings (Loss) Per63

Note 12 - Earnings (Loss) Per Share (Details Textual) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 11, 2015	Jan. 30, 2015
Series J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.001	$ 0.001		$ 0.001	$ 0.001
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	265.8	180.5	88.1

Note 12 - Computation of Basic

Note 12 - Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Controlling Shareholders [Member] | Series H, I and J Preferred Stock [Member]
Deemed dividends	$ (23,263,854)	$ (49,687,773)	$ (20,206,288)
Controlling Shareholders [Member] | Series K Preferred Stock [Member]
Deemed dividends	1,147,766
Controlling Shareholders [Member] | Accretion of Series K Preferred Stock [Member]
Deemed dividends	$ (14,312,298)
Controlling Shareholders [Member] | Pegasus Warrant [Member]
Deemed dividends		$ 570,574
Controlling Shareholders [Member]
Loss before taxes	$ (20,449,368)	(52,134,928)	$ (74,506,560)
Undistributed net loss	$ (56,877,755)	$ (101,252,127)	$ (94,712,848)
Basic and diluted weighted average number of common shares outstanding (in shares)	303,742,731	232,409,186	170,662,220
Basic and diluted net loss per weighted average common share attributable to controlling shareholders (in dollars per share)	$ (0.19)	$ (0.44)	$ (0.55)
Noncontrolling Shareholders [Member] | Series H, I and J Preferred Stock [Member]
Deemed dividends	$ (7,551,762)	$ (12,827,960)	$ (4,152,304)
Noncontrolling Shareholders [Member] | Series K Preferred Stock [Member]
Deemed dividends	(1,147,766)
Noncontrolling Shareholders [Member] | Accretion of Series K Preferred Stock [Member]
Deemed dividends	$ (4,645,966)
Noncontrolling Shareholders [Member] | Pegasus Warrant [Member]
Deemed dividends		$ (570,574)
Noncontrolling Shareholders [Member]
Loss before taxes	$ (6,638,142)	(13,459,745)	$ (15,310,772)
Undistributed net loss	$ (19,983,635)	$ (26,858,279)	$ (19,463,076)
Basic and diluted weighted average number of common shares outstanding (in shares)	98,598,998	60,001,396	35,070,340
Basic and diluted net loss per weighted average common share attributable to controlling shareholders (in dollars per share)	$ (0.20)	$ (0.45)	$ (0.55)
Loss before taxes	$ (27,071,008)	$ (65,594,673)	$ (89,817,332)
Deemed dividends	$ (20,106,030)	$ 0	$ 0

Note 13 - Related Party Trans65

Note 13 - Related Party Transactions (Details Textual) - USD ($)	Dec. 07, 2015	Aug. 28, 2014	Jan. 09, 2014	Jan. 03, 2014	Feb. 19, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 11, 2015	Jan. 30, 2015
Pegasus Guaranty Warrants [Member]
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants					$ 3,300,000
Dividends, Preferred Stock, Stock						$ 571,000
T&M Protection Resources [Member]
Related Party Transaction, Expenses from Transactions with Related Party						$ 3,000	$ 12,000	$ 14,000
Holdings III [Member ] | Series J Redeemable Convertible Preferred Stock [Member]
Preferred Units, Issued									10,000	11,525
Shares Issued, Price Per Share						$ 1,000				$ 1,000
Proceeds from Other Equity						$ 21,500,000
Pegasus Fund IV [Member] | Series K Warrant [Member]
Shares Issued, Price Per Share	$ 1,000
Security Units Issued	20,106.03					20,106.03
Riverwood [Member] | Series J Redeemable Convertible Preferred Stock [Member]
Preferred Units, Issued				2,860
Proceeds from Other Equity				$ 2,900,000
Zouk [Member] | Series J Redeemable Convertible Preferred Stock [Member]
Preferred Units, Issued			2,570				2,570
Proceeds from Other Equity			$ 2,600,000
PCA Holdings [Member] | Series J Redeemable Convertible Preferred Stock [Member]
Preferred Units, Issued		8,000	4,000	2,000			14,000
Proceeds from Other Equity		$ 8,000,000	$ 4,000,000
Holdings II [Member] | Series J Redeemable Convertible Preferred Stock [Member]
Preferred Units, Issued				6,000			6,000
Pegasus Guaranty [Member]
Debt Issuance Cost					$ 2,800,000
Interest Expense, Related Party						$ 553,000	$ 476,000
Series J Redeemable Convertible Preferred Stock [Member]
Preferred Units, Issued							38,475	20,000
Proceeds from Other Equity				$ 8,000,000
Debt Issuance Cost						3,300,000	$ 3,200,000
Related Party Transaction, Expenses from Transactions with Related Party						$ 0	$ 919,000	$ 2,200,000

Note 14 - Equity Based Compen66

Note 14 - Equity Based Compensation Plans (Details Textual) - USD ($)	Sep. 09, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 0
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Stock or Unit Option Plan Expense		$ 2,100,000	$ 3,300,000	$ 6,900,000
2011 Employee Stock Purchase Plan [Member] | Minimum [Member]
Stock Issued Employee Stock Purchase Plan Average Price Per Share		$ 0.13
2011 Employee Stock Purchase Plan [Member] | Maximum [Member]
Stock Issued Employee Stock Purchase Plan Average Price Per Share		$ 2.32
2011 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,800,000
Percentage of Compensation to Purchase Share		30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee		2,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		85.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans		9,975	23,126	88,284
Covered Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	7,000,000		30,000,000
Directors Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Outstanding, Number		1,150,456
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 3,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	55,000,000		155,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		24,416,277
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		90,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		3 years 138 days
Restricted Stock or Unit Expense		$ 121,000	$ 730,000	$ 891,000

Note 14 - Stock Option Activity

Note 14 - Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Outstanding, number of shares (in shares) | shares	44,281,364
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	24,416,277
Granted (in dollars per share) | $ / shares	$ 0.14
Forfeited or expired, number of shares (in shares) | shares	(8,570,994)
Forfeited or expired (in dollars per share) | $ / shares	$ 1.07
Outstanding, number of shares (in shares) | shares	60,126,647
Outstanding, weighted average exercise price (in (in dollars per share) | $ / shares	$ 0.31
Outstanding as of December 31, 2015	8 years 127 days
Vested or expected to vest as of December 31, 2015 (in shares) | shares	48,712,673
Vested or expected to vest as of December 31, 2015 (in dollars per share) | $ / shares	$ 0.35
Vested or expected to vest as of December 31, 2015	8 years 58 days
Exercisable as of December 31, 2015 (in shares) | shares	17,577,168
Exercisable as of December 31, 2015 (in dollars per share) | $ / shares	$ 0.64
Exercisable as of December 31, 2015	6 years 167 days

Note 14 - Stock Options Outstan

Note 14 - Stock Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Range 1 [Member]
Range of Exercise Price – Lower (in dollars per share)	$ 0.11
Range of Exercise Price – Upper (in dollars per share)	$ 0.11
Options Outstanding (in shares) | shares	14,024,257
Options Outstanding Weighted Average Remaining Contractual Term	9 years 292 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 0.11
Options Exercisable (in shares) | shares	2,326,445
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 0.11
Range 2 [Member]
Range of Exercise Price – Lower (in dollars per share)	0.13
Range of Exercise Price – Upper (in dollars per share)	$ 0.13
Options Outstanding (in shares) | shares	3,132,020
Options Outstanding Weighted Average Remaining Contractual Term	9 years 321 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 0.13
Range 3 [Member]
Range of Exercise Price – Lower (in dollars per share)	0.18
Range of Exercise Price – Upper (in dollars per share)	$ 0.18
Options Outstanding (in shares) | shares	27,800,000
Options Outstanding Weighted Average Remaining Contractual Term	8 years 281 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 0.18
Options Exercisable (in shares) | shares	6,950,000
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 0.18
Range 4 [Member]
Range of Exercise Price – Lower (in dollars per share)	0.20
Range of Exercise Price – Upper (in dollars per share)	$ 1
Options Outstanding (in shares) | shares	12,091,998
Options Outstanding Weighted Average Remaining Contractual Term	6 years 153 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 0.55
Options Exercisable (in shares) | shares	5,714,248
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 0.89
Range 5 [Member]
Range of Exercise Price – Lower (in dollars per share)	1.04
Range of Exercise Price – Upper (in dollars per share)	$ 4.35
Options Outstanding (in shares) | shares	3,069,122
Options Outstanding Weighted Average Remaining Contractual Term	4 years 3 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 1.70
Options Exercisable (in shares) | shares	2,577,225
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 1.77
Range 6 [Member]
Range of Exercise Price – Lower (in dollars per share)	7.40
Range of Exercise Price – Upper (in dollars per share)	$ 7.40
Options Outstanding (in shares) | shares	3,000
Options Outstanding Weighted Average Remaining Contractual Term	1 year 40 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 7.40
Options Exercisable (in shares) | shares	3,000
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 7.40
Range 7 [Member]
Range of Exercise Price – Lower (in dollars per share)	10.80
Range of Exercise Price – Upper (in dollars per share)	$ 10.80
Options Outstanding (in shares) | shares	6,250
Options Outstanding Weighted Average Remaining Contractual Term	1 year 215 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 10.80
Options Exercisable (in shares) | shares	6,250
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 10.80
Options Outstanding (in shares) | shares	60,126,647
Options Outstanding Weighted Average Remaining Contractual Term	8 years 127 days
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 0.31
Options Exercisable (in shares) | shares	17,577,168
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 0.64

Note 14 - Other Information Per

Note 14 - Other Information Pertaining to Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Weighted average grant date fair value per share of options (in dollars per share)	$ 0.11	$ 0.14	$ 0.39

Note 14 - Other Information P70

Note 14 - Other Information Pertaining to Stock Options (Details) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Unnvested as of (in shares) | shares	2,080,342
Unnvested as of (in dollars per share) | $ / shares	$ 0.38
Granted (in shares) | shares	2,033,905
Granted (in dollars per share) | $ / shares	$ 0.20
Vested (in shares) | shares	(2,221,177)
Vested (in dollars per share) | $ / shares	$ 0.36
Forfeited (in shares) | shares	(1,693,070)
Forfeited (in dollars per share) | $ / shares	$ 0.21
Unvested as of (in shares) | shares	200,000
Unvested as of (in dollars per share) | $ / shares	$ 0.20

Note 14 - Weighted Average Assu

Note 14 - Weighted Average Assumptions Used to Value Stock Option Grants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Minimum [Member]
Exercise price (in dollars per share)	$ 0.11	$ 0.18	$ 0.44
Fair market value of the underlying stock on date of grant (in dollars per share)	$ 0.11	$ 0.18	$ 0.38
Risk-free interest rate	1.31%	0.209%	1.03%
Expected life, in years	5 years 21 days	1 year 273 days	6 years
Expected volatility	91.86%	67.32%	99.51%
Share Price	$ 0.12	$ 0.12	$ 0.08
Maximum [Member]
Exercise price (in dollars per share)	0.24	0.50	0.70
Fair market value of the underlying stock on date of grant (in dollars per share)	$ 0.24	$ 0.42	$ 0.64
Risk-free interest rate	1.68%	2.07%	2.00%
Expected life, in years	6 years 91 days	6 years 91 days	6 years 91 days
Expected volatility	102.48%	100.46%	101.82%
Share Price	$ 0.28	$ 0.28	$ 0.52
Expected dividend yield	0.00%	0.00%	0.00%
Expected forfeiture rate	14.93%	19.19%	7.49%

Note 15 - Restructuring Expen72

Note 15 - Restructuring Expense (Details Textual)	Sep. 24, 2012USD ($)	May. 31, 2012	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)
Multi-Year Initiatives [Member] | MEXICO | Non-cash Impairment [Member]
Restructuring Costs and Asset Impairment Charges	$ 1,700,000
Multi-Year Initiatives [Member] | MEXICO
Restructuring and Related Cost, Number of Positions Eliminated	520
Multi-Year Initiatives [Member] | UNITED STATES
Restructuring and Related Cost Number of Management Positions Replaced		10
Multi-Year Initiatives [Member]
Restructuring and Related Cost, Number of Positions Eliminated			69
Written Down Amount of Property Plant Equipment of Foreign Subsidiaries			$ 3,200,000
Restructuring and Related Cost, Expected Cost Remaining				$ 394,000

Note 15 - Restructuring Expen73

Note 15 - Restructuring Expense and Related Charges (Details) - USD ($)		12 Months Ended	24 Months Ended	36 Months Ended
		Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2015
Facility Closing [Member] | MEXICO
Restructuring charges	[1]			$ 102,688
Facility Closing [Member]
Restructuring charges	[2]	$ 1,883,326	$ 3,314,251	4,479,076
Organization Optimization Initiative [Member]
Restructuring charges	[3]		114,277	77,061
Restructuring charges		$ 1,883,326	$ 3,428,528	$ 4,658,825
[1]	On September 24, 2012, the Company's Board of Directors committed to the closing of our manufacturing facility in Mexico, which was substantially complete as of December 31, 2013. The Mexico Closing resulted in the termination of approximately 520 employees and $1.7 million in a non-cash asset impairment.
[2]	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company's manufacturing to its contract manufacturers in Asia, related workforce reduction in Satellite Beach, Florida of approximately 69 positions, including the termination of several members of the Company's senior management and a $3.2 million write-down of property and equipment, cost reductions in our foreign subsidiaries and refocusing the Company's efforts within North America, which resulted in the elimination of all employees at LSGBV and LSIPL.
[3]	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company's continued shift of its manufacturing and production processes to the Company's contract manufacturer in Mexico, the replacement of ten members of management in the United States, following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company's offices in the United Kingdom and Australia. As of December 31, 2014, this plan was complete.

Note 15 - Accrued Liability Ass

Note 15 - Accrued Liability Associated with Restructuring Charges (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Facility Closing [Member]
Accrued liability	$ 959,240	$ 699,832
Charges	297,770	2,496,184
Payments	(1,117,625)	(2,236,776)
Accrued liability	139,385	959,240
Payments	(1,117,625)	$ (2,236,776)
Excess Facilities [Member]
Accrued liability	$ 311,269
Charges		$ 311,269
Payments	$ (69,776)
Accrued liability	241,493	$ 311,269
Payments	(69,776)
Other Exit Costs [Member]
Accrued liability	$ 180,840	$ 276,956
Charges		122,054
Payments	$ (167,960)	(218,170)
Accrued liability	12,880	180,840
Payments	(167,960)	(218,170)
Accrued liability	1,451,349	976,788
Charges	297,770	2,929,507
Payments	(1,355,361)	(2,454,946)
Accrued liability	393,758	1,451,349
Payments	$ (1,355,361)	$ (2,454,946)

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2007
Unrecognized Tax Benefits	$ 0	$ 0
Income Tax Examination, Penalties and Interest Accrued	$ 0	$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%	34.00%
Deferred Tax Assets, Valuation Allowance	$ 203,452,854	$ 198,689,826
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 4,800,000
Net Operating Loss Carryforwards				$ 75,000,000

Note 16 - Consolidated Income T

Note 16 - Consolidated Income Tax Provision (Benefit) from Continuing Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Domestic	$ (26,652,135)	$ (64,343,390)	$ (86,599,121)
Foreign	(418,873)	(1,251,283)	(3,218,211)
Loss before income tax expense	$ (27,071,008)	$ (65,594,673)	$ (89,817,332)

Note 16 - Reconciliation of the

Note 16 - Reconciliation of the Provision for Income Taxes from Continuing Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Loss before taxes	$ (27,071,008)	$ (65,594,673)	$ (89,817,332)
Income tax benefit applying United States federal statutory rate of 34%	(9,204,143)	(22,302,189)	(30,537,893)
State taxes, net of federal benefit	(776,264)	(1,183,397)	(1,674,412)
Derivative fair value adjustment	203,498	$ 5,359,878	(1,323,618)
Other	26,037		40,669
Increase in valuation allowance	4,763,028	$ 30,513,501	31,336,114
Change in effective tax rate - United States	(2,910,847)	(2,679,697)	1,597,640
Expiration/true-up of NOL's	7,840,050	(10,236,058)	110,950
Rate difference between United States federal statutory rate and Netherlands statutory rate	$ 58,642	175,180	$ 450,550
Other		$ 352,782

Note 16 - Reconciliation of t78

Note 16 - Reconciliation of the Provision for Income Taxes from Continuing Operations (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%	34.00%

Note 16 - Deferred Income Taxes

Note 16 - Deferred Income Taxes Reflect the Net Tax Effects of Temporary Differences (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Net operating loss carryforwards	$ 188,129,680	$ 181,983,692
Stock based compensation	9,825,558	8,957,780
Inventories	2,569,531	2,864,989
Warranty liability	1,235,724	1,745,093
Fixed asset impairment	616,709	1,168,224
Accrued legal fees	945,664	552,889
Goodwill impairment on asset acquisition	459,591	871,229
Accrued rebates	843,340	448,481
Accounts receivable	165,495	138,221
Accrued compensation	154,130	357,750
Charitable contribution carryforward	67,682	56,979
Depreciation	66,987	$ 66,775
Accrued Expenses	55,691
India start-up costs	$ 33,136	$ 32,645
Reserve for losses on non-cancelable purchase commitments		172,110
Accrued Florida use tax		830
Total deferred income tax assets	$ 205,168,916	199,417,687
Less: valuation allowance	(203,452,854)	(198,689,826)
Net deferred tax assets	1,716,063	727,861
Stock losses	(171,976)	$ (169,409)
Interest Expense	(14,004)
Loss on disposal of long-lived assets	(1,530,083)	$ (558,452)
Total deferred income tax liabilities	$ (1,716,063)	$ (727,861)
Net deferred tax liabilities

Note 16 - Tax Loss Carryforward

Note 16 - Tax Loss Carryforwards Available to Offset Future Income Taxes (Details)	Dec. 31, 2015USD ($)
Internal Revenue Service (IRS) [Member]
2,016
2,017
2,018	$ 5,357,429
2,019	2,293,432
2,020	1,473,066
2,021	2,769,043
2,022	1,840,300
2,023	2,031,270
2,024	3,353,481
2,025	2,293,432
2,026	2,293,432
2,027	9,937,230
2,028	29,631,134
2,029	33,916,312
2,030	50,887,617
2,031	67,057,312
2,032	90,683,320
2,033	82,316,468
2,034	59,822,398
2,035	28,057,263
Total	476,013,939
Tax and Customs Administration, Netherlands [Member]
2,016	3,869,995
2,017	4,265,206
2,018	4,692,440
2,019	908,706
2,020	908,568
2,021	$ 2,027,511
2,022
2,023
2,024
2,025
2,026
2,027
2,028
2,029
Total	$ 16,672,426

Note 17 - Concentrations of C81

Note 17 - Concentrations of Credit Risk (Details Textual) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Sales Revenue, Net [Member]
Number of Customers	1	1	1
Concentration Risk, Percentage	91.00%	80.00%	55.00%
Accounts Receivable [Member]
Number of Customers	1	1
Concentration Risk, Percentage	70.00%	66.00%

Note 18 - Commitments and Con82

Note 18 - Commitments and Contingencies (Details Textual) - USD ($)	Dec. 22, 2015	Dec. 04, 2015	Nov. 25, 2015	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Geveran Case [Member] | J.P. Morgan [Member]
Appeal Bond		$ 20,100,000
Geveran Case [Member] | J.P. Morgan and Lighting Science Group Corporation [Member]
Appeal Bond		40,200,000
Geveran Case [Member]
Loss Contingency, Damages Sought, Value					$ 25,000,000
Loss Contingency, Damages Awarded, Value			$ 40,200,000
Appeal Bond		$ 20,100,000
Amount Required to Stay of Execution Sought by Plaintiff [Member]
Appeal Bond	$ 40,200,000
Long-term Purchase Commitment, Amount					9,200,000
Operating Leases, Rent Expense, Net					459,000	$ 1,700,000	$ 2,100,000
Loss Contingency, Damages Sought, Value					25,000,000
Litigation Settlement, Amount				$ 200,000
Litigation Settlement, Commissions Receivable				1,700,000	1,700,000
Litigation Settlement, Percentage of Future Sales Receivable				$ 5	$ 5

Note 18 - Summary of Commitment

Note 18 - Summary of Commitments Under Operating Leases for Property and Equipment (Details)	Dec. 31, 2015USD ($)
2,016	$ 398,461
2,017	317,777
2,018	276,705
2,019	$ 276,705
2,020
Thereafter
	$ 1,269,648

Note 19 - Defined Contributio84

Note 19 - Defined Contribution Plan (Details Textual) - USD ($)	7 Months Ended	12 Months Ended	24 Months Ended	36 Months Ended
	Aug. 01, 2011	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2015
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount		$ 135,000	$ 220,000	$ 303,000

Note 20 - Company's Consolidate

Note 20 - Company's Consolidated Quarterly Results of Operations (Details) - USD ($)	3 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Controlling Shareholders [Member]
Basic and diluted net loss per weighted average common share attributable to controlling shareholders (in dollars per share)	$ (0.03)	$ (0.04)	$ (0.01)	$ (0.07)	$ (0.09)	$ (0.04)	$ (0.04)	$ (0.33)
Noncontrolling Shareholders [Member]
Basic and diluted net loss per weighted average common share attributable to controlling shareholders (in dollars per share)	$ (0.03)	$ (0.04)	$ (0.01)	$ (0.07)	$ (0.09)	$ (0.04)	$ (0.04)	$ (0.35)
Revenue	$ 17,520,465	$ 19,587,399	$ 23,270,363	$ 19,371,545	$ 22,441,799	$ 23,089,356	$ 19,827,864	$ 25,925,841
Gross margin	(369,184)	5,223,665	3,416,535	2,930,248	(3,648,278)	3,420,353	1,119,562	2,690,495
Net income (loss)	$ (11,311,451)	$ 269,344	$ (2,444,313)	$ (13,601,090)	$ (11,769,618)	$ (2,102,576)	$ (11,628,516)	$ (40,093,963)

Note 21 - Valuation and Quali86

Note 21 - Valuation and Qualifying Accounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts [Member]
2,015	$ 408,047	$ 509,561	$ 1,188,366
2,015	(1,097)	(8,574)	7,381
2,015	$ 83,105	$ 103,792	$ 279,757
2,015
2,015	$ (15,031)	$ (196,732)	$ (965,943)
2,015	475,024	408,047	509,561
Provision for Purchase Commitments [Member]
2,015	540,227	1,629,806	$ 5,678,992
2,015	(1,260)	(13,556)
2,015	115,926	507,257	$ 1,283,444
2,015	(643,648)	(1,217,878)	(4,562,550)
2,015	$ (11,245)	(365,402)	(770,080)
2,015		$ 540,227	$ 1,629,806

Note 22 - Subsequent Events (De

Note 22 - Subsequent Events (Details Textual) - Holdings III [Member ] - Series J Redeemable Convertible Preferred Stock [Member] - Subsequent Event [Member] $ in Millions	Feb. 23, 2016USD ($)shares
Stock Issued During Period, Shares, New Issues | shares	3,000
Proceeds from Issuance of Redeemable Preferred Stock | $	$ 3